EP2270197A2 - Cibles, procédés et réactifs pour le diagnostic et le traitement de la schizophrénie - Google Patents

Cibles, procédés et réactifs pour le diagnostic et le traitement de la schizophrénie Download PDF

Info

Publication number
EP2270197A2
EP2270197A2 EP10172269A EP10172269A EP2270197A2 EP 2270197 A2 EP2270197 A2 EP 2270197A2 EP 10172269 A EP10172269 A EP 10172269A EP 10172269 A EP10172269 A EP 10172269A EP 2270197 A2 EP2270197 A2 EP 2270197A2
Authority
EP
European Patent Office
Prior art keywords
calcineurin
schizophrenia
compound
susceptibility
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10172269A
Other languages
German (de)
English (en)
Other versions
EP2270197A3 (fr
Inventor
David J Gerber
Maria Karayiorgou
Tsuyoshi Miyakawa
Susumu Tonegawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
Massachusetts Institute of Technology
Original Assignee
Rockefeller University
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rockefeller University, Massachusetts Institute of Technology filed Critical Rockefeller University
Publication of EP2270197A2 publication Critical patent/EP2270197A2/fr
Publication of EP2270197A3 publication Critical patent/EP2270197A3/fr
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Definitions

  • Schizophrenia is a severe psychiatric condition that affects approximately one percent of the population worldwide ( Lewis, D. A. & Lieberman, J. A. (2000) Neuron 28, 325-3 ).
  • the disease is characterized by a variety of so-called "positive" symptoms that tend to occur episodically, including hallucinations, delusions, paranoia, and psychosis and/or relatively persistent symptoms such as flattened affect, social withdrawal, impaired attention, and cognitive impairments. Symptoms in the latter category are frequently referred to as "negative symptoms”.
  • the present invention relates to the identification of targets for the diagnosis and treatment of schizophrenia and related conditions.
  • the invention encompasses the observation that calcineurin mutant mice have a phenotype suggestive of schizophrenia and that locations of calcineurin subunit genes and numerous other genes encoding polypeptides that play a role in calcineurin signaling are coincident with schizophrenia susceptibility loci.
  • calcineurin abbreviated herein as CaN or CN
  • components of the calcineurin signaling pathway in the pathogenesis of schizophrenia and/or related conditions.
  • the invention provides a variety of methods for diagnosis of schizophrenia or related conditions, e.g., by modulating calcineurin activity and/or calcium homeostasis.
  • the invention provides a method for the diagnosis of schizophrenia or schizophrenia susceptibility comprising: (i) providing a sample obtained from a subject to be tested for schizophrenia or schizophrenia susceptibility; and
  • the invention provides methods for the detection of polymorphisms, mutations, variations, alterations in expression, etc., in such genes and/or in their mRNA or protein expression products for use in the diagnosis of schizophrenia or related conditions or susceptibility to schizophrenia or related conditions. Such methods are useful for various purposes, including diagnosis.
  • the invention provides a number of different in vitro and in vivo methods of screening for compounds useful in treating schizophrenia and/or related conditions including methods of screening for compounds in various animal models.
  • the invention provides compounds identified according to these screening methods, and pharmaceutical compositions including these compounds.
  • the invention provides a variety of methods of treating schizophrenia or susceptibility to schizophrenia.
  • the invention provides a method for treating schizophrenia or susceptibility to schizophrenia comprising: (i) providing a subject at risk of or suffering from schizophrenia; and (ii) administering a compound that modulates activity or abundance of calcineurin, a calcineurin subunit, or a calcineurin interacting molecule to the subject.
  • the invention further provides a method for treating schizophrenia or susceptibility to schizophrenia comprising: (i) providing a subject at risk of or suffering from schizophrenia; and (ii) administering a compound that modulates intracellular calcium levels to the subject.
  • the compounds for use in the various treatment methods described herein may be identified according to any of the inventive screens described herein, or using other approaches.
  • the invention also provides a method for treating schizophrenia or susceptibility to schizophrenia comprising: (i) providing a subject at risk of or suffering from schizophrenia; and (ii) administering a compound that modulates hippocampal or cortical LTD to the subject.
  • the invention additionally provides a method for treating schizophrenia or susceptibility to schizophrenia comprising: (i) providing a subject at risk of or suffering from schizophrenia; and (ii) administering a compound that modulates expression or activity of one or more NFAT-regulated proteins.
  • the invention further provides a method for treating an immune system condition in a subject having schizophrenia or susceptibility to schizophrenia comprising: (i) providing a subject at risk of or suffering from an immune system abnormality and at risk of or suffering from schizophrenia; and (ii) administering a compound that modulates activity or abundance of calcineurin, a calcineurin subunit, or a calcineurin interacting molecule to the subject.
  • the invention further provides reagents such as oligonucleotides, oligonucleotide arrays, antibodies, and transgenic mice, including knockout and knockdown mice, and methods for their use in performing screens for compounds useful in treating schizophrenia or related conditions.
  • reagents such as oligonucleotides, oligonucleotide arrays, antibodies, and transgenic mice, including knockout and knockdown mice, and methods for their use in performing screens for compounds useful in treating schizophrenia or related conditions.
  • Figure 2 presents data showing decreased social interaction and increased anxiety-like behavior in CNB-deficient mice.
  • Figure 2A compares the total distance traveled by wild type and CNB-deficient mice during the open field test.
  • Figure 2B compares the number of transitions between the light and dark compartments by wild type and CNB-deficient mice during the open field test.
  • Figure 2C compares the total amount of time spent in the light compartment by wild type and CNB-deficient mice during the open field test.
  • Figure 2D compares distance traveled by wild type and CNB-deficient mice during the social interaction test.
  • Figure 2E compares the number of active contacts made by wild type and CNB-deficient mice during the social interaction test.
  • Figure 2F compares the mean duration of contacts made by wild type and CNB-deficient mice during the social interaction test.
  • Figure 3 compares prepulse inhibition in wild type and CNB-deficient mice at various startle stimulus intensities, showing impaired prepulse inhibition in CNB-deficient mice.
  • Figure 4 compares percent freezing in wild type and CNB-deficient during the latent inhibition test, showing impaired latent inhibition in CNB-deficient mice.
  • Figure 5 presents schematic illustrations of calcineurin and its related molecules.
  • Figure 5A Calcineurin dephosphorylates DARPP-32 or inhibitor-1 relieving inhibition of PPI. Blockade of NMDA receptor by PCP and inhibition of calcineurin by cyclosporin A or FK-506 have been shown to cause psychosis or psychotic behavior.
  • Figure 5B Activation of calcineurin by calcium influx leads to dephosphorylation and translocation of NF-AT to the nucleus required for activation of NF-AT mediated transcription. Modified from Snyder et al., 1998.
  • Figure 5C The calcium releasing channels RyR and IP3R are physically complexed with FKBP12 and calcineurin.
  • FIG. 6 is a schematic drawing of the PPP3CC gene locus.
  • Figure 6A shows he location of the PPP3CC gene in the 8p21.3 region is depicted in relation to relevant markers from linkage studies.
  • Figure 6B shows an expanded view of the PPP3CC gene including the exon/intron structure and the locations of the SNPs used for association studies and the coding sequence mutation identified in exon 5.
  • FIG. 6 is a schematic diagram of the PPP3CC locus. The location of the PPP3CC gene in the 8p21.3 region is depicted in relation to relevant markers from linkage studies in Figure 6A.
  • Figure 6B presents an expanded view of the PPP3CC gene including the exon/intron structure and the locations of the SNPs used for association studies and the coding sequence mutation identified in exon 5.
  • D8S136 Pulver et al., 1995, Brzustowicz et al., 1999; D8S1771: Blouin et al., 1998, Gurling et al., 2001; D8S1752: Blouin et al., 1998; D8S1715, D8S133: Kendler et al., 1996. Distances and positions in this figure are according to the Nov. 2002, human draft sequence.
  • Figure 6C shows haplotype distribution and transmission at the PPP3CC locus. T/nT: Transmitted/non-Transmitted.
  • Figure 7A is a photo of an agarose gel showing products of PCR amplification of cDNA from human adult total brain, fetal total brain and testis and demonstrating PPP3CC expression in human brain.
  • Figure 7B is a photo of an agarose gel showing products of PCR amplification of cDNA from human adult brain regions
  • agonist refers to a molecule that increases or prolongs the duration of the effect of a polypeptide or a nucleic acid.
  • Agonists may include proteins, nucleic acids, carbohydrates, lipids, small molecules, ions, or any other molecules that modulate the effect of the polypeptide or nucleic acid.
  • An agonist may be a direct agonist, in which case it is a molecule that exerts its effect by binding to the polypeptide or nucleic acid, or an indirect agonist, in which case it exerts its effect via a mechanism other than binding to the polypeptide or nucleic acid (e.g., by altering expression or stability of the polypeptide or nucleic acid, by altering the expression or activity of a target of the polypeptide or nucleic acid, by interacting with an intermediate in a pathway involving the polypeptide or nucleic acid, etc.)
  • allele refers to one of the different forms of a gene or DNA sequence that can exist at a single locus within the genome.
  • the term includes both naturally occurring alleles, which are typically studied in genetic linkage and association studies, and genetically engineered alleles.
  • antagonist refers to a molecule that decreases or reduces the duration of the effect of a polypeptide or a nucleic acid.
  • Antagonists may include proteins, nucleic acids, carbohydrates, or any other molecules that modulate the effect of the polypeptide or nucleic acid.
  • An antagonist may be a direct antagonist, in which case it is a molecule that exerts its effect by binding to the polypeptide or nucleic acid, or an indirect antagonist, in which case it exerts its effect via a mechanism other than binding to the polypeptide or nucleic acid (e.g., by altering expression or stability of the polypeptide or nucleic acid, by altering the expression or activity of a target of the polypeptide or nucleic acid, by interacting with an intermediate in a pathway involving the polypeptide or nucleic acid, etc.)
  • Antibody refers to an immunoglobulin, whether natural or wholly or partially synthetically produced. All derivatives thereof which maintain specific binding ability are also included in the term. The term also covers any protein having a binding domain which is homologous or largely homologous to an immunoglobulin binding domain. These proteins may be derived from natural sources, or partly or wholly synthetically produced. An antibody may be monoclonal or polyclonal. The antibody may be a member of any immunoglobulin class, including any of the human classes: IgG, IgM, IgA, IgD, and IgE.
  • the antibody may be a fragment of an antibody such as an Fab, F(ab') 2, Fv or other fragment that retains an antigen binding site, or a recombinantly produced scFv fragment.
  • the term includes "humanized" antibodies in which for example, a variable domain of rodent origin is fused to a constant domain of human origin, thus retaining the specificity of the rodent antibody. It is noted that the domain of human origin need not originate directly from a human in the sense that it is first synthesized in a human being. Instead, "human” domains may be generated in rodents whose genome incorporates human immunoglobulin genes. See, e.g., Vaughan, et al., (1998), Nature Biotechnology, 16: 535-539 . An antibody may be polyclonal or monoclonal, though for purposes of the present invention monoclonal antibodies are generally preferred.
  • diagnostic information or information for use in diagnosis is any information that is useful in determining whether a patient has a disease or condition and/or in classifying the disease or condition into a phenotypic category or any category having significance with regards to the prognosis of or likely response to treatment (either treatment in general or any particular treatment) of the disease or condition.
  • diagnosis refers to providing any type of diagnostic information, including, but not limited to, whether a subject is likely to have a condition (such as schizophrenia), information related to the nature or classification of a disease, information related to prognosis and/or information useful in selecting an appropriate treatment.
  • gene generally has its meaning as understood in the art. However, it will be appreciated by those of ordinary skill in the art that the term may have a variety of meanings in the art, some of which include gene regulatory sequences (e.g., promoters, enhancers, etc.) and/or intron sequences, 3' untranslated regions, etc., and others of which are limited to coding sequences. It will further be appreciated that definitions of gene include references to nucleic acids that do not encode proteins but rather encode functional RNA molecules, e.g., tRNAs, stRNAs, etc. Thus the term gene may refer to a portion of a nucleic acid that encodes a protein and may optionally encompass regulatory sequences. This definition is not intended to exclude application of the term "gene" to non-protein coding expression units but rather to clarify that, in most cases, the term as used in this document refers to a nucleic acid that includes a protein coding region.
  • gene regulatory sequences e.g., promoters, enhancers,
  • a gene product or expression product, or gene expression product is, in general, an RNA transcribed from the gene or a polypeptide encoded by an RNA transcribed from the gene.
  • homology refers to a degree of similarity between two or more nucleic acid sequences or between two or more amino acid sequences.
  • homologous sequences may be identified by searching databases (e.g., GenBank, EST [expressed sequence tag]databases, GST [gene sequence tag] databases, GSS [genome survey sequence] databases, organism sequencing project databases) using computer programs such as BLASTN for nucleotide sequences and BLASTP, gapped BLAST, and PSI-BLAST for amino acid sequences. These programs are described in Altschul, SF, et al., Basic local alignment search tool, J. Mol.
  • hybridize refers to the interaction between two complementary nucleic acid sequences.
  • the phrase hybridizes under high stringency conditions describes an interaction that is sufficiently stable that it is maintained under art-recognized high stringency conditions.
  • Guidance for performing hybridization reactions can be found, for example, in Current Protocols in Molecular Biology, John Wiley & Sons, N.Y., 6.3.1-6.3.6, 1989 , and more recent updated editions, all of which are incorporated by reference. See also Sambrook, Russell, and Sambrook, Molecular Cloning: A Laboratory Manual, 3rd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 2001 . Aqueous and nonaqueous methods are described in that reference and either can be used.
  • various levels of stringency are defined, such as low stringency (e.g., 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by two washes in 0.2X SSC, 0.1 % SDS at least at 50°C (the temperature of the washes can be increased to 55°C for medium-low stringency conditions)); 2) medium stringency hybridization conditions utilize 6X SSC at about 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 60°C; 3) high stringency hybridization conditions utilize 6X SSC at about 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 65°C; and 4) very high stringency hybridization conditions are 0.5M sodium phosphate, 0.1 % SDS at 65°C, followed by one or more washes at 0.2X SSC, 1% SDS at 65°C.) Hybrid
  • the parameters for different degrees of stringency will generally differ based on various factors such as the length of the hybridizing sequences, whether they contain RNA or DNA, etc. For example, appropriate temperatures for high, medium, or low stringency hybridization will generally be lower for shorter sequences such as oligonucleotides than for longer sequences. Additional examples of hybridization conditions of varying stringency are found, for example, in Ausubel, et al., Current Protocols in Molecular Biology, John Wiley & Sons, N.Y., edition as of March 2002 .
  • Isolated means 1) separated from at least some of the components with which it is usually associated in nature; and/or 2) not occurring in nature.
  • linkage or linked generally refers to genetic linkage.
  • Two loci e.g., a DNA marker locus and a disease locus such as a mutation causing disease
  • linkage or linked may also refer to physical linkage.
  • two loci are physically linked when they are present on the same contiguous piece of DNA. The greater the physical distance between the two loci, the less the degree of physical linkage. It will be appreciated that although there is a correspondence between genetic and physical linkage, the correspondence may be imprecise and can be nonlinear.
  • two loci that are separated by any particular number of bases may be closely linked genetically if the recombination frequency in the region between the loci is low, but may be essentially genetically unlinked or only weakly linked if the recombination frequency between the two loci is high.
  • oligonucleotide refers to a single stranded nucleic acid (typically DNA) ranging in length from 2 to approximately 70 bases. Oligonucleotides are often synthetic but can also be produced from naturally occurring polynucleotides.
  • An oligonucleotide probe or primer is an oligonucloetide capable of binding to a target nucleic acid of complementary sequence through one or more types of chemical bonds, usually through complementary pairing via hydrogen bond formation. Oligonucleotide probes and/or primers are often 5 to 60 bases and in specific embodiments may be between 10 and 40, or 15 and 30 bases long.
  • An oligonucleotide probe or primer may include natural (e.g., A, G, C or T) or modified bases (7-deazaguanosine, inosine, etc.).
  • the bases may be joined by a linkage other than a phosphodiester bond, such as a phosphoramidite linkage or a phosphorothioate linkage, or they may be peptide nucleic acids in which the constituent bases are joined by peptide bonds rather than by phosphodiester bonds, so long as such linkages do not interfere with hybridization.
  • Any of the oligonucleotides described herein may be provided in isolated form or purified form.
  • operable linked in reference to nucleic acids, refers to a relationship between two nucleic acid sequences wherein the expression or processing of one of the nucleic acid sequences is controlled by, regulated by, modulated by, etc. the other nucleic acid sequence.
  • a promoter is operably linked with a coding sequence if the promoter controls transcription of the coding sequence.
  • a nucleic acid sequence that is operably linked to a second nucleic acid sequence is covalently linked, either directly or indirectly, to such a sequence, although any effective three-dimensional association is acceptable.
  • nucleic acid or polypeptide that regulates the expression, processing, localization, transport, etc., of a second nucleic acid or polypeptide, generally one to which it is chemically or physically bound (e.g., covalently linked, hydrogen bonded, associated via ionic bonds).
  • polymorphism refers to the occurrence of two or more alternative sequences or alleles in a population.
  • a polymorphic site is a location at which differences in genomic DNA sequence exist among members of a population.
  • a polymorphic variant is any of the alternate sequences or alleles that may exist at a polymorphic site among members of a population.
  • population may refer to the population of the world, or to any subset or group of individuals.
  • polymorphic variant as used herein generally refers to naturally occurring variants as opposed, for example, to variants created by recombinant DNA technology. However, the term includes variants created by recombinant DNA technology when such variants replicate or duplicate naturally occurring variants.
  • Replication or duplication of naturally occurring variants is intended to include recapitulation of a naturally occurring human variant either in a different human genetic background or in an animal model such as a mouse (e.g., the creation of a mutation at a corresponding site within mouse genomic DNA).
  • primer refers to a single-stranded oligonucleotide which acts as a point of initiation of template-directed DNA synthesis under appropriate conditions (e.g., in the presence of four different nucleoside triphosphates and a polymerization agent, such as DNA polymerase, RNA polymerase or reverse transcriptase) in an appropriate buffer and at a suitable temperature.
  • a polymerization agent such as DNA polymerase, RNA polymerase or reverse transcriptase
  • the appropriate length of a primer depends on the intended use of the primer, but typically ranges from approximately 10 to approximately 30 nucleotides. Short primer molecules generally require lower temperatures to form sufficiently stable hybrid complexes with the template.
  • a primer need not be perfectly complementary to the template but should be sufficiently complementary to hybridize with it.
  • primer site refers to the sequence of the target DNA to which a primer hybridizes.
  • primer pair refers to a set of primers including a 5' (upstream) primer that hybridizes with the 5' end of a DNA sequence to be amplified and a 3' (downstream) primer that hybridizes with the complement of the 3' end of the sequence to be amplified. These primers are also referred to as forward and reverse primers respectively.
  • Purified means separated from many other compounds or entities.
  • a compound or entity may be partially purified, substantially purified, or pure, where it is pure when it is removed from substantially all other compounds or entities, i.e., is preferably at least about 90%, more preferably at least about 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or greater than 99% pure.
  • regulatory sequence or regulatory element is used herein to describe a region of nucleic acid sequence that directs, enhances, or inhibits the expression (particularly transcription, but in some cases other events such as splicing or other processing) of sequence(s) with which it is operatively linked.
  • the term includes promoters, enhancers and other transcriptional control elements.
  • regulatory sequences may direct constitutive expression of a nucleotide sequence; in other embodiments, regulatory sequences may direct cell type or tissue-specific and/or inducible expression.
  • tissue-specific promoters appropriate for use in mammalian cells include lymphoid-specific promoters (see, for example, Calame et al., Adv. Immunol.
  • promoters of T cell receptors see, e.g., Winoto et al., EMBO J. 8:729, 1989
  • immunoglobulins see, for example, Banerji et al., Cell 33:729, 1983 ; Queen et al., Cell 33:741, 1983
  • neuron-specific promoters e.g., the neurofilament promoter; Byrne et al., Proc. Natl. Acad. Sci. USA 86:5473, 1989 ).
  • promoters are also encompassed, including, for example, the murine hox promoters ( Kessel et al., Science 249:374, 1990 ) and the ⁇ -fetoprotein promoter ( Campes et al., Genes Dev. 3:537,1989 ).
  • a sample obtained from a subject may include, but is not limited to, any or all of the following: a cell or cells, a portion of tissue, blood, serum, ascites, urine, saliva, amniotic fluid, cerebrospinal fluid, and other body fluids, secretions, or excretions.
  • the sample may be a tissue sample obtained, for example, from skin, muscle, buccal or conjunctival mucosa, placenta, gastrointestinal tract or other organs.
  • a sample of DNA from fetal or embryonic cells or tissue can be obtained by appropriate methods, such as by amniocentesis or chorionic villus sampling.
  • sample also includes any material derived by isolating, purifying, and/or processing such a sample.
  • Derived samples may include nucleic acids or proteins extracted from the sample or obtained by subjecting the sample to techniques such as amplification or reverse transcription of mRNA, etc.
  • a short, interfering RNA comprises an RNA duplex that is approximately 19 basepairs long and optionally further comprises one or two single-stranded overhangs or loops.
  • An siRNA may comprise two RNA strands hybridized together, or may alternatively comprise a single RNA strand that includes a self-hybridizing portion.
  • siRNAs include one or more free strand ends, it is generally preferred that free 5' ends have phosphate groups, and free 3' ends have hydroxyl groups.
  • one strand of the siRNA (or, the self-hybridizing portion of the siRNA) is precisely complementary with a region of the target transcript, meaning that the siRNA hybridizes to the target transcript without a single mismatch.
  • perfect complementarity is not necessary. For certain siRNAs (e.g., microRNAs), perfect complementarity is not desirable.
  • siRNA is considered to be targeted for the purposes described herein if 1) the stability of the target gene transcript is reduced in the presence of the siRNA as compared with its absence; and/or 2) the siRNA shows at least about 90%, more preferably at least about 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% precise sequence complementarity with the target transcript for a stretch of at least about 17, more preferably at least about 18 or 19 to about 21-23 nucleotides; and/or 3) the siRNA hybridizes to the target transcript under stringent conditions.
  • the term specific binding refers to an interaction between a target polypeptide (or, more generally, a target molecule) and a binding molecule such as an antibody, agonist, or antagonist, which may be a small molecule.
  • the interaction is typically dependent upon the presence of a particular structural feature of the target polypeptide such as an antigenic determinant or epitope recognized by the binding molecule (e.g., in the case of an antibody).
  • a particular structural feature of the target polypeptide such as an antigenic determinant or epitope recognized by the binding molecule
  • an antibody is specific for epitope A
  • the presence of a polypeptide containing epitope A or the presence of free unlabeled A in a reaction containing both free labeled A and the antibody thereto will reduce the amount of labeled A that binds to the antibody.
  • specificity need not be absolute.
  • numerous antibodies cross-react with other epitopes in addition to those present in the target molecule.
  • Such cross-reactivity may be acceptable depending upon the application for which the antibody is to be used.
  • the degree of specificity of an antibody will depend on the context in which it is being used. In general, an antibody exhibits specificity for a particular partner if it favors binding of that partner above binding of other potential partners.
  • One of ordinary skill in the art will be able to select antibodies having a sufficient degree of specificity to perform appropriately in any given application (e.g., for detection of a target molecule, for therapeutic purposes, etc).
  • interaction is also typically dependent upon the presence of a particular structural feature of the target polypeptide, e.g., a cleft or three-dimensional pocket into which the small molecule fits, etc.
  • treating includes reversing, alleviating, inhibiting the progress of, preventing, or reducing the likelihood of the disease, disorder, or condition to which such term applies, or one or more symptoms or manifestations of such disease, disorder or condition.
  • vector is used herein to refer to a nucleic acid molecule capable of mediating entry of, e.g., transferring, transporting, etc., another nucleic acid molecule into a cell.
  • the transferred nucleic acid is generally linked to, e.g., inserted into, the vector nucleic acid molecule.
  • a vector may include sequences that direct autonomous replication, or may include sequences sufficient to allow integration into host cell DNA.
  • Useful vectors include, for example, plasmids, cosmids, and viral vectors.
  • Viral vectors include, e.g., replication defective retroviruses, adenoviruses, adeno-associated viruses, and lentiviruses.
  • viral vectors may include various viral components in addition to nucleic acid(s) that mediate entry of the transferred nucleic acid.
  • CNB-deficient mice exhibited increases in (1) locomoter activity; (2) stereotyped behavior; (3) exploratory behavior towards inanimate objects; and (4) anxiety-like behavior.
  • CNB mutant mice also displayed decreased social interaction, impaired prepulse inhibition, impaired latent inhibition, and impaired nesting behavior. Most or all of these abnormalities are considered to indicate disturbances in cognitive functioning corresponding to disturbances found in human subjects suffering from schizophrenia and/or related conditions. Many of them are also found in other currently available genetic mouse models and/or in mice treated with pharmacological compounds (e.g., cocaine, PCP), known to induce schizophrenia-like symptoms in human subjects.
  • pharmacological compounds e.g., cocaine, PCP
  • calcineurin interacting molecules and “calcineurin interacting genes” or as “calcineurin signaling molecules” and “calcineurin signaling genes”.
  • calcineurin is required for certain types of NMDA receptor-dependent synaptic plasticity including long term depression (LTD) (Mulkey, et al 1994, Zeng, et al, 2001).
  • LTD long term depression
  • calcineurin activity is likely to affect the range of bidirectional synaptic modification.
  • the involvement of calcineurin in dopaminergic and glutamatergic signaling events raises the possibility that calcineurin function is required as a critical link between these two neurotransmitter systems.
  • calcineurin with the ryanodine receptor type 3 (RYR3)/inositol triphosphate receptor 1 (ITPR1) complex has been shown to regulate intracellular calcium release ( Cameron, A. M., et al. (1995) Cell 83, 463-72 . Furthermore, calcineurin activity has been shown to be required for expression of the ITPR1 receptor in neurons ( Genazzani, A. A., Carafoli, E. & Guerini, D. (1999) Proc Natl Acad Sci U S A 96, 5797-801 ). Therefore, altered calcineurin activity could lead to abnormal neuronal calcium homeostasis.
  • calcineurin is required for the NFAT-mediated transcriptional response ( Crabtree, G. R. & Olson, E. N. (2002) Cell 109 Suppl, S67-79 ). At least one isoform of NFAT is expressed in the mammalian brain (Plyte 2001). Calcineurin activity has been shown to be required for the expression of specific genes in neurons (Genazzani 1999) consistent with the possibility that altered calcineurin activity could lead to changes in calcium-dependent neuronal transcription that could have profound effects on neuronal function.
  • Calcineurin is a calcium-dependent serine/threonine protein phosphatase that is highly expressed in the central nervous system ( Klee, C. B., Ren, H. & Wang, X. (1998) J Biol Chem 273, 13367-70 ; Shibasaki, F., Hallin, U. & Uchino, H. (2002) J Biochem (Tokyo) 131, 1-15 ; Rusnak, F. and Mertz, P., Physiological Reviews (2000) 80(4): 1483-1522 and references therein, all of which are incorporated by reference herein.).
  • Calcineurin consists of a heterodimer composed of a regulatory subunit, CNB, and a catalytic subunit CNA. There are three different CNA isoforms, referred to as CNA ⁇ , CNA ⁇ , and CNA ⁇ , encoded by distinct genes. Binding of the CNA subunit to the Ca 2+ /calmodulin complex appears to be required for activity.
  • the CNB subunit is structurally related to calmodulin and is also needed for full CN activity.
  • CNB which is typically myristoylated, generally remains associated with CNA in the absence of Ca 2+ , but phosphatase activity increases when Ca 2+ binds to the B subunit.
  • Calcineurin exerts its effects through a variety of different mechanisms.
  • One major mechanism of action involves control of transcription via regulation of the NF-AT family of transcription factors ( Shaw, J.P., et al. (1988), Science, 241: 202-205 ; Flanagan, W.M. (1991), Nature, 352: 803-7 ; Liu, J., et al. (1991), Cell, 66: 807-15 ; reviewed in Crabtree, G. (2001), J. Biol. Chem., 276(4): 2313-2316 , and see also references therein.) Briefly, NF-AT family members contain two components, one of which (NFATc) is present in the cytoplasm while the other (NFATn) is present in the nucleus.
  • Calcineurin functions in the NF-AT pathway by directly dephosphorylating NF-ATc subunits, which then translocate into the nucleus where they associate with the nuclear component to form active complexes that regulate transcription of a diverse set of genes containing NF-AT responsive regulatory elements (e.g., promoters). Calcineurin also acts in a variety of other ways, including some that are independent of transcription.
  • CN and/or CN subunits interact (either directly, as by physical interaction, or indirectly, as by any other mechanism not requiring physical interaction) with a variety of other cellular molecules.
  • these molecules may alter any of a number of aspects of CN function, level, or activity. Alternately, the activity, level, or function of these CN-interacting molecules may be altered by the activity of CN.
  • certain of these molecules e.g., Cabin1 are endogenous inhibitors of CN; others are substrates (e.g., NF-ATc), channels or receptors, etc.
  • CN, CN subunit, or CN interacting molecule may include, but is not limited to, molecules or molecular complexes that possess calcineurin activity or subunits thereof (e.g., molecules or molecular complexes that dephosphorylate known CN substrates at sites known to be sites of dephosphorylation by CN); molecules that alter or modulate (e.g., enhance or inhibit) calcineurin activity; molecules that regulate calcineurin expression (which includes regulation of expression of any CN subunit or other CN interacting molecule), intracellular location, and/or functional activity; calcineurin substrates; channels, pumps, or receptors that regulate intracellular calcium levels or localization so as to alter or influence CN activity; molecules that modify and/or post-translationally process CN, CN subunit(s) and/or CN interacting molecules; and molecules that enhance or antagonize the effects of calcineurin.
  • molecules or molecular complexes that possess calcineurin activity or subunits thereof
  • calcineurin interacting molecules include calcium channels such as the capacitance regulated activation channels (CRAC; Serafini, T., et al., Immunity, 3, 239-250, 1995 ; Fanger, C., et al., J. Cell. Biol., 131, 655-667, 1995 ; Timmerman, L., et al., Nature, 383, 837-40, 1996 ), L-type calcium channels, calcium pumps, etc.
  • CRAC capacitance regulated activation channels
  • this subset includes the following: CNB; CNA ⁇ ; CNA ⁇ ; CNA ⁇ ; Cabin 1; calcineurin B homologous protein; calcipressins (e.g., DSCR-1); calsarcin-1, calsarcin-3; A kinase anchor protein 5; FK506 binding protein 5; interleukin enhancer binding factor 2 (ILF2 subunit of nuclear factor of activated T cells); nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 2; ryanodine receptor type 3; IP3 (inositol triphosphate) receptor type 1; pituitary adenylate cyclase activating polypeptide (PACAP); calcium-signal modulating cyclophilin ligand; and various other molecules that interact with calcineurin activity.
  • calcineurin B homologous protein e.g., DSCR-1
  • calsarcin-1 calsarcin-3
  • schizophrenia is believed to be a multigenic disorder in which mutations or variations in many different genes may contribute, to different degrees and in different combinations, to development of disease. It appears likely that contributions from multiple genes are involved in any given patient, and that mutations or alterations in these genes display varying degrees of penetrance so that even if an individual harbors a mutation or alteration that may contribute to schizophrenia pathogenesis, the individual may not develop clinical disease.
  • Genetic studies include linkage studies, in which families having an increased incidence of schizophrenia relative to the incidence in the general population (referred to herein as "schizophrenia families" are studied) and association studies, in which populations typically containing both related and unrelated subjects diagnosed with schizophrenia, e.g., groups of schizophrenia families, are studied. Association studies can compare the frequencies of certain haplotypes in control and affected populations. Alternately, they can assess disequilibrium in the transmission of certain haplotypes to affected probands.
  • a "haplotype” can be a specific polymorphic variant for a given polymorphism on a single chromosome, or the combination of polymorphic variants (alleles) for a group of polymorphisms represented on a single chromosome for a particular individual.
  • a population may contain multiple subpopulations of individuals each of which has a different DNA sequence at a particular chromosomal location.
  • Such polymorphisms may be single nucleotide differences (single nucleotide polymorphisms, referred to herein as SNPs).
  • SNPs When SNPs occur within coding regions they may, but frequently do not, result in alterations in the amino acid sequence of the encoded protein. In general, while not wishing to be bound by any theory, SNPs are thought to arise as a result of mutations in what was originally a more homogeneous ancestral sequence. Other polymorphisms include multiple nucleotide polymorphisms, deletions (including microdeletions), insertions, inversions, translocations, etc.
  • polymorphisms may be responsible for disease or phenotypic variation by, for example, causing a functional alteration in an encoded protein
  • many polymorphisms appear to be silent in that no known detectable difference in phenotype exists between individuals having different alleles.
  • polymorphisms may be physically and/or genetically linked to genes or DNA sequences in which mutations or variations confer susceptibility to and/or play a causative role in disease (i.e., they are located within a contiguous piece of DNA).
  • polymorphisms that are physically linked to such mutations or variations will generally be inherited together with the mutation or alteration.
  • Schizophrenia is one of a group of psychiatric conditions and disorders that exhibit a spectrum of similar phenotypes. Many of these conditions and disorders are found at increased frequency in family members of schizophrenic subjects, relative to their incidence in the general population. These factors make it likely that the same genetic mutations or alterations that contribute to schizophrenia susceptibility and/or pathogenesis are also involved in susceptibility to and/or pathogenesis of these conditions and disorders. Thus the methods and reagents of the invention are also applicable to these related conditions and disorders.
  • Conditions related to schizophrenia may include, but are not limited to: schizoaffective disorder, schizotypal personality disorder, schizotypy, atypical psychotic disorders, avoidant personality disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), and obsessive compulsive disorder (OCD).
  • DSM-III, DSM III-R, DSM-IV, or DSM IV-R DSM-III-R, DSM-IV, or DSM IV-R.
  • the invention will be described in terms of schizophrenia itself.
  • the methods and reagents may also be used in a similar manner with respect to these conditions and disorders as described for schizophrenia itself.
  • compounds identified as potential prophylactic or therapeutic agents for schizophrenia may also be utilized for treatment and/or prevention of these related disorders.
  • the following sections provide further description of the various aspects of the invention.
  • the invention provides a variety of methods for the diagnosis of schizophrenia or schizophrenia susceptibility.
  • the invention provides a method for the diagnosis of schizophrenia or schizophrenia susceptibility comprising: (i) providing a sample obtained from a subject to be tested for schizophrenia or schizophrenia susceptibility; and (ii) detecting a polymorphic variant of a polymorphism in a coding or noncoding portion of gene encoding a calcineurin subunit or a calcineurin interacting molecule, or detecting a polymorphic variant of a polymorphism in a genomic region linked to a coding or noncoding portion of a gene encoding a calcineurin subunit or a calcineurin interacting molecule in the sample.
  • the sample itself will typically consist of cells (e.g., blood cells), tissue, etc., removed from the subject.
  • the subject can be an adult, child, fetus, or embryo.
  • the sample is obtained prenatally, either from the fetus or embryo or from the mother (e.g., from fetal or embryonic cells in that enter the maternal circulation).
  • the sample may be further processed before the detecting step. For example, DNA in the cell or tissue sample may be separated from other components of the sample, may be amplified, etc. All samples obtained from a subject, including those subjected to any sort of further processing, are considered to be obtained from the subject.
  • the polymorphism in general, if the polymorphism is located in a gene, it may be located in a noncoding or coding region of the gene. If located in a coding region the polymorphism may, but frequently will not, result in an amino acid alteration. Such alteration may or may not have an effect on the function or activity of the encoded polypeptide. If the polymorphism is linked to, but not located within, a gene, it is preferred that the polymorphism is closely linked to the gene. For example, it is preferred that the recombination frequency between the polymorphism and the gene is less than approximately 20%, preferably less than approximately 10%, less than approximately 5%, less than approximately 1%, or still less.
  • the gene is coincident with a mapped or identified schizophrenia susceptibility locus.
  • the gene may encode any of the molecules listed in Table 1.
  • the gene encodes the CNA ⁇ subunit.
  • the inventive methods also encompass genes coincident with schizophrenia susceptibility loci that have yet to be mapped or identified. By “coincident with” is meant either that the gene or a portion thereof falls within the identified chromosomal location or is located in close proximity to that location. In general, the resolution of studies identifying genetic susceptibility loci may be on the order of tens of centimorgans.
  • close proximity refers to within 20 centimorgans of either side of the susceptibility locus, more preferably within 10 centimorgans of either side of the susceptibility locus, yet more preferably within 5 centimorgans of either side of the susceptibility locus.
  • susceptibility loci are designated by the chromosomal band positions that they span (e.g., 8p21 refers to chromosome 8, arm p, band 21; 8p20-21 refers to chromosome 8, arm p, bands 20-21 inclusive) and may be defined at higher resolution (e.g., 8p21.1).
  • the terms “coincident with” and “close proximity” may be interpreted in light of the knowledge of one of ordinary skill in the art.
  • genes that are expressed in the nervous system may be particularly attractive candidates as schizophrenia susceptibility genes.
  • Such genes may be expressed throughout the brain or in particular regions or cell types or regions in the brain such as cell types or regions (e.g., forebrain, cortex, hippocampus, etc.) implicated in schizophrenia pathogenesis.
  • cell types or regions e.g., forebrain, cortex, hippocampus, etc.
  • Schizophrenia susceptibility genes may also be expressed outside the brain in addition to, or instead of, within the brain.
  • the DNA is sequenced, and the sequence (referred to as a "subject sequence") is compared with a reference sequence, which is typically taken to represent the "normal” or “wild type” sequence.
  • a reference sequence which is typically taken to represent the "normal” or “wild type” sequence.
  • Such a sequence may be, for example, the human draft genome sequence, publicly available in various databases mentioned in Example 3, or a sequence deposited in a database such as GenBank.
  • this analysis does not necessarily presuppose that either the subject sequence or the reference sequence is the "normal", most common, or wild type sequence. It is the fact that a difference in nucleotide sequence is identified at a particular site that determines that a polymorphism exists at that site.
  • polymorphic variants In most instances, particularly in the case of SNPs, only two polymorphic variants will exist at any location. However, in the case of SNPs, up to four variants may exist since there are four naturally occurring nucleotides in DNA. Other polymorphisms such as insertions may have more than four alleles.
  • any of a variety of methods may be employed to detect the existence of any particular polymorphic variant in a subject.
  • a subject may have either the reference sequence or an alternate sequence at the site.
  • the phrase "detecting a polymorphism” or "detecting a polymorphic variant” as used herein generally refers to determining which of two or more polymorphic variants exists at a polymorphic site, although "detecting a polymorphism” may also refer to the process of initially determining that a polymorphic site exists in a population. The meaning to be given to these phrases will be clear from the context as interpreted in light of the knowledge of one of ordinary skill in the art.
  • a subject may be said to exhibit the polymorphism.
  • any individual will exhibit either one or two possible variants at the polymorphic site (one on each chromosome). (This may, however, not be the case if the individual exhibits one more chromosomal abnormalities such as deletions.)
  • Detection of a polymorphism or polymorphic variant in a subject may be performed by sequencing, similarly to the manner in which the existence of a polymorphism is initially established as described above. However, once the existence of a polymorphism is established a variety of more efficient methods may be employed. Many such methods are based on the design of oligonucleotide probes or primers that facilitate distinguishing between two or more polymorphic variants.
  • Probes typically refers to oligonucleotides that hybridize in a base-specific manner to a complementary nucleic acid molecule.
  • probes and primers include polypeptide nucleic acids, as described in Nielsen et al, Science, 254, 1497-1500 (1991 ).
  • the term "primer” in particular generally refers to a single-stranded oligonucleotide that can act as a point of initiation of template-directed DNA synthesis using methods such as PCR (polymerase chain reaction), LCR (ligase chain reaction), etc.
  • a probe or primer will comprise a region of nucleotide sequence that hybridizes to at least about 8, more often at least about 10 to 15, typically about 20-25, and frequently about 40, 50 or 75, consecutive nucleotides of a nucleic acid molecule.
  • a probe or primer comprises 100 or fewer nucleotides, preferably from 6 to 50 nucleotides, preferably from 12 to 30 nucleotides.
  • the probe or primer is at least 70% identical to the contiguous nucleotide sequence or to the complement of the contiguous nucleotide sequence, preferably at least 80% identical, more preferably at least 90% identical, even more preferably at least 95% identical, or having an even higher degree of identity.
  • a preferred probe or primer is capable of selectively hybridizing to a target contiguous nucleotide sequence or to the complement of the contiguous nucleotide sequence.
  • a probe or primer further comprises a label, for example by incorporating a radioisotope, fluorescent compound, enzyme, or enzyme co-factor.
  • Oligonucleotides that exhibit differential or selective binding to polymorphic sites may readily be designed by one of ordinary skill in the art.
  • an oligonucleotide that is perfectly complementary to a sequence that encompasses a polymorphic site i.e., a sequence that includes the polymorphic site within it or at one or the other end
  • PCR Primer A Laboratory Manual, Dieffenbach, C.W. and Dveksler, G. S. (Eds .); PCR Basics: From Background to Bench, Springer Verlag, 2000 ; M. J.
  • Other amplification methods include the ligase chain reaction (LCR) ( Wu and Wallace, Genomics, 4:560 (1989 ), Landegren et al., Science, 241:1077 (1988 ), transcription amplification ( Kwoh et al., Proc. Natl. Acad. Sci.
  • hybridization methods such as Southern analysis, Northern analysis, or in situ hybridizations, can be used (see Current Protocols in Molecular Biology, Ausubel, F. et al., eds., John Wiley & Sons ).
  • a sample e.g., a sample comprising genomic DNA, RNA, or cDNA
  • a subject suspected of being susceptible to or having schizophrenia is obtained from a subject suspected of being susceptible to or having schizophrenia.
  • the hybridization sample is maintained under conditions selected to allow specific hybridization of the nucleic acid probe to a region encompassing the polymorphic site.
  • Specific hybridization can be performed under high stringency conditions or moderate stringency conditions, for example, as described above.
  • the hybridization conditions for specific hybridization are high stringency.
  • the probe may be perfectly complementary to the region to which it hybridizes, i.e., perfectly complementary to a region encompassing the polymorphic site when the site contains any particular polymorphic sequence.
  • Multiple nucleic acid probes e.g., multiple probes differing only at the polymorphic site, or multiple probes designed to detect polymorphic variants at multiple polymorphic sites may be used concurrently in this method.
  • restriction digest analysis can be used to detect the existence of a polymorphic variant of a polymorphism, if alternate polymorphic variants of the polymorphism result in the creation or elimination of a restriction site.
  • a sample containing genomic DNA is obtained from the individual.
  • Polymerase chain reaction (PCR) can be used to amplify a region comprising the polymorphic site, and restriction fragment length polymorphism analysis is conducted (see Current Protocols in Molecular Biology, referenced above).
  • the digestion pattern of the relevant DNA fragment indicates the presence or absence of a particular polymorphic variant of the polymorphism and is therefore indicative of the presence or absence of susceptibility to schizophrenia.
  • the array typically includes oligonucleotide probes capable of specifically hybridizing to different polymorphic variants.
  • a nucleic acid of interest e.g., a nucleic acid encompassing a polymorphic site
  • Hybridization and scanning are generally carried out according to standard methods. See, e.g., Published PCT Application Nos. WO 92/10092 and WO 95/11995 , and U.S. Pat. No. 5,424,186 .
  • the array is scanned to determine the position on the array to which the nucleic acid hybridizes.
  • the hybridization data obtained from the scan is typically in the form of fluorescence intensities as a function of location on the array.
  • the invention provides, for each of the CC-21, CC-33, CC-S3, and CC-5 polymorphisms, a primer that terminates at the nucleotide position immediately adjacent to a polymorphic site on the 3' side and extends at least 8 and less than 100 nucleotides in the 5' direction from this site. It is noted that the foregoing includes two classes of primers, having sequences representing both DNA strands. According to certain embodiments of the invention the primer extends at least 10, at least 12, at least 15, or at least 20 nucleotides in the 5' direction. According to certain embodiments of the invention the primer extends less than 80, less than 60, less than 50, less than 40, less than 30, or less than 30 nucleotides in the 5'direction.
  • Kits may include any of the components mentioned above, in addition to further components specific for hybridization and processing of oligonucleotide arrays.
  • Appropriate software i.e., computer-readable instructions stored on a computer-readable medium
  • Such software may, for example, provide the user with an indication of the genotype of a sample and/or provide an assessment of the degree of susceptibility of the subject to schizophrenia, or an assessment of the likelihood that the subject suffers from schizophrenia.
  • the present invention provides an antibody able to specifically bind to a calcineurin subunit or calcineurin interacting molecule, wherein the subunit or molecule is encoded by a gene within or linked to a schizophrenia susceptibility locus, or within which a functional mutation causing or contributing to susceptibility or development of schizophrenia may exist.
  • the invention provides an antibody able to specifically bind to a variant of such a calcineurin subunit or calcineurin interacting molecule, wherein the presence of the variant in a subject is indicative of susceptibility to or presence of schizophrenia.
  • Such antibodies are able to distinguish between calcineurin subunits or calcineurin interacting molecules that differ at sites encoded by polymorphic variants.
  • the invention may be desirable to develop and/or select antibodies that specifically bind to particular regions of the polypeptide, e.g., the extracellular domain. Such specificity may be achieved by immunizing the animal with peptides or polypeptide fragments that correspond to that region. Alternately, a panel of monoclonal antibodies can be screened to identify those that specifically bind to the desired region. As mentioned above, according to certain embodiments of the invention the antibodies specifically bind to antigenic determinants that comprise a region encoded by a polymorphic site. According to certain embodiments of the invention such antibodies are able to distinguish between molecules that differ by a single amino acid. In particular, the invention provides antibodies capable of specifically binding to CNA ⁇ , or a portion thereof, including amino acid 163, wherein amino acid 163 is either glutamine or arginine. Any of the antibodies described herein may be labeled.
  • the term "significant reactivity" refers to an antibody or antibody fragment, which, when applied to a tissue of interest under conditions suitable for immunohistochemistry, will elicit either no staining or negligible staining, e.g., only a few positive cells scattered among a field of mostly negative cells.
  • the functional activity of a calcineurin subunit or calcineurin interacting molecule in sample obtained from a subject is detected and/or measured and is compared with the activity of the calcineurin subunit or interacting molecule that would be expected in a sample obtained from a normal subject.
  • the calcineurin subunit or calcineurin interacting molecule is one that is encoded by a gene within or linked to a schizophrenia susceptibility locus, or within which a functional mutation causing or contributing to susceptibility or development of schizophrenia may exist. It will be appreciated that the particular assay to be employed in detecting and/or measuring the functional activity will depend on the particular molecule being assayed.
  • the cell line expressing all desired components may be treated with calcium ionophore plus PMA to stimulate calcineurin activity which may be measured by assessing activity of the NF-AT reporter construct (e.g., NFAT-luciferase) [22-24].
  • NF-AT reporter construct e.g., NFAT-luciferase
  • Comparison of reporter activity in absence or presence of compounds is used to identify compounds that yield altered (e.g., increased or decreased) NFAT-mediated transcription.
  • these compounds will be those that increase or decrease NFAT activity directly, or indirectly either through calcineurin or other interactions.
  • the same assay can be performed with all members of the pathway present except specific calcineurin subunits, or in presence of constitutively active forms of NF-AT 45 kD subunit. This may entail using cell lines deficient for specific calcineurin subunits, or inactivating specific subunits by RNAi during the assay.
  • the inventive screen may also be performed in the presence of siRNA targeted to one or more transcripts encoding one or more specific calcineurin catalytic subunits, e.g., to screen for compounds that specifically target a single expressed calcineurin catalytic subunit.
  • biological system any vessel, well, or container in which biomolecules (e.g., nucleic acids, polypeptides, polysaccharides, lipids, etc.) are placed; a cell or population of cells; a tissue; an organism, etc.
  • biomolecules e.g., nucleic acids, polypeptides, polysaccharides, lipids, etc.
  • the biological system is a cell or population of cells, but the method can also be performed in a vessel using purified or recombinant proteins.
  • This assay can also be used in combination with transfection or addition of calcineurin inhibitory proteins such as Cabin 1 or CHP to screen for compounds that activate calcineurin by interfering with binding between calcineurin and inhibitory proteins. Again specificity could be determined by repeating the assay in absence of inhibitor protein gene transfection or by using RNAi to inhibit expression of the inhibitory protein.
  • calcineurin inhibitory proteins such as Cabin 1 or CHP
  • the screen is performed in the presence of siRNA targeted to CNA ⁇ and/or CNA ⁇ to specifically screen for compounds that target CNA ⁇ -dependent calcineurin activity.
  • the screen is performed in cell lines that are deficient for CNA ⁇ or CNA ⁇ to specifically screen for compounds that target CNA ⁇ -dependent calcineurin activity. Identified compounds may then be tested in similar assays in which CNA ⁇ and/or CNA ⁇ is/are present and CNA ⁇ activity is absent to test for the CNA ⁇ specificity of the compounds.
  • the above screening methods will also yield compounds that decrease or inhibit NF-AT activity or could be readily modified to do so, e.g., by employing a reporter that exhibits a high degree of basal NF-AT activity, and screening for reduction in activity.
  • the invention provides a method of identifying a candidate compound for treatment of schizophrenia or susceptibility to schizophrenia comprising steps of: (i) providing a biological system comprising phosphorylated calcineurin substrate and calcineurin; (ii) contacting the biological system with a compound; (iii) comparing the extent or rate of dephosphorylation of the substrate with the extent or rate of dephosphorylation occurring or expected to occur in the absence of the compound.
  • the compound is identified as a modulator of calcineurin activity and a candidate compound for treatment of schizophrenia or susceptibility to schizophrenia.
  • Similar cell-based assays can be performed, in which cells expressing CN (and optionally any CN interacting protein(s)) and a CN substrate are exposed to a candidate compound.
  • Such cells may endogenously express CN and/or the CN interacting molecules and CN substrate or may be transfected/electroporated with one or more constructs encoding any of these components.
  • the cells Preferably the cells also express (or are engineered to express) upstream components necessary for or contributing to phosphorylation of the CN substrate.
  • the CN substrate is isolated from the cell and the extent or rate of dephosphorylation (or phosphorylation) is measured and compared with the degree of dephosphorylation (or phosphorylation) in cells not exposed to the compound.
  • An increase in the extent or rate of dephosphorylation (or phosphorylation) in cells exposed to the compound is indicative that the compound is an activator (or inhibitor) of CN phosphatase activity
  • a decrease in extent or rate of dephosphorylation (or phosphorylation) in cells exposed to the compound is indicative that the compound is an inhibitor (or activator) of CN phosphatase activity.
  • the mechanism of such inhibition or activation may be direct or indirect.
  • specificity of the screen is achieved by performing the screen in the absence of CNA ⁇ and CNA ⁇ as described above. Subunit specificity of the screen can then be assessed by performing the screen in presence of CNA ⁇ or CNA ⁇ and absence of CNA ⁇ . Compounds that modulate (i.e. enhance or suppress) CNA ⁇ -dependent calcineurin activity are identified by this screen.
  • the cell-based screens measure dephosphorylation or phosphorylation may depend on the extent to which the substrate is normally phosphorylated in the cell.
  • the cell is treated with a compound that results in increased phosphorylation of the CN substrate prior to performing the assay.
  • cells may be treated with an appropriate agonist, e.g., dopamine, to put DARPP-32/inhibitor 1 in a phosphorylated state.
  • the calcineurin pathway may be activated at a sub-saturating level with PMA and ionomycin in the presence and absence of candidate compounds.
  • IP3 Receptor Type 1 Including Ligands.
  • the invention provides a variety of methods to identify compounds that modulate the activity of the IP3 receptor type 1 as candidate compounds for treatment of schizophrenia or schizophrenia susceptibility.
  • One such method comprises identification of compounds that modulate the binding of labeled inositol 1,4,5- triphosphate (IP3) to the IPTR1 receptor.
  • IP3 labeled inositol 1,4,5- triphosphate
  • ER endoplasmic reticulum
  • membranes from cells expressing the IPTR1 receptor are isolated and incubated in the presence of labeled IP3 (e.g., [3H]-IP3 or any other form of labeled IP3 can be used).
  • Cells can be pretreated with candidate compound prior to isolation of the membranes, or compounds can be added to the isolated membrane preparation prior to, following, or during exposure to a candidate compound.
  • Specificity can be assessed by examining the effects of compounds on calcium release in cells that do not express the IP3 receptor type 1, or in combination with siRNA targeted to transcripts encoding IP3 receptor type 1. If the compound is specific its effects in such cells should be substantially less than in cells expressing IP3 receptor type 1.
  • Other methods for detecting compounds that alter binding of IP3 to the membrane preparation, not employing labeled IP3, are also within the scope of the invention.
  • Compounds that alter the binding of the labeled IP3 to the membrane preparation are candidate agents for treatment of schizophrenia or schizophrenia susceptibility.
  • the compounds may also be used for any purpose for which it is desired to modulate the activity of the IP3 receptor type 1. It is noted that the ryanodine receptor type 3 and the IP3 receptor type 1 form a complex, and compounds that affect the formation of this complex, e.g., by inhibiting or activating formation of the complex, are included within the scope of the invention.
  • compounds including neuropeptides, neurotransmitter receptor agonists and antagonists, and ion channel antagonists (e.g., ion channel blockers) and agonists, and compounds that interact with components of major neuronal signal transduction cascades including kinases and phosphatases are screened for the ability to modulate (reduce or enhance) LTD.
  • the ability to modulate LTD in hippocampal slices Numerous such compounds are known, and one of ordinary skill in the art will generally be able to identify many such compounds by a review of the scientific literature. Methods for measurement of LTD are also known in the art.
  • the molecular targets of compounds that modulate LTD are candidate drug targets for schizophrenia and related diseases, and once identified, the invention includes screens for small molecules that bind to these targets as candidate compounds for treatment of schizophrenia or susceptibility to schizophrenia.
  • the invention provides methods for rational drug design based on molecular modeling for identification of candidate compounds for treatment of schizophrenia or schizophrenia susceptibility, e.g., using the three-dimensional structure (crystal structure, NMR solution structure, etc.) of CN and/or calcineurin complexes including other components of the calcineurin signaling pathway. Such methods may be particularly useful, e.g., to identify compounds that may interfere with binding between CaN and an inhibitory protein or to identify compounds that interfere with the auto-inhibitory domain of calcineurin.
  • the crystal structure of calcineurin and of the FKBP12-FK506-calcineurin complex have been reported [51, 52].
  • the subject that receive the compound and those that do not receive the compound are genetically similar or identical animals.
  • the animal is a CNB-deficient mouse.
  • the compound is any compound identified according to any of the inventive compound screening methods described herein, e.g., a compound that modulates activity or abundance of calcineurin, a calcineurin subunit, or a calcineurin interacting molecule to the subject.
  • a "transgenic animal” is a non-human animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal includes a transgene.
  • Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, amphibians, and the like.
  • a transgene is exogenous DNA or a rearrangement, e.g., a deletion of endogenous chromosomal DNA, which preferably is integrated into or occurs in the genome of the cells of a transgenic animal.
  • knockout animals are included.
  • a transgene can, but need not, replace an endogenous gene.
  • a transgene can direct the expression of an encoded product in one or more cell types or tissues of the transgenic animal.
  • siRNA-triggered gene silencing A number of variations in structure, length, number of mismatches, size of loop, identity of nucleotides in overhangs, etc., are consistent with effective siRNA-triggered gene silencing. While not wishing to be bound by any theory, it is thought that intracellular processing (e.g., by DICER) of a variety of different precursors results in production of siRNA capable of effectively mediating gene silencing. Generally it is preferred to target exons rather than introns, and it may also be preferable to select sequences complementary to regions within the 3' portion of the target transcript. Generally it is preferred to select sequences that contain approximately equimolar ratio of the different nucleotides and to avoid stretches in which a single residue is repeated multiple times.
  • Antisense nucleic acids are generally single-stranded nucleic acids (DNA, RNA, modified DNA, or modified RNA) complementary to a portion of a target nucleic acid (e.g., an mRNA transcript) and therefore able to bind to the target to form a duplex.
  • a target nucleic acid e.g., an mRNA transcript
  • oligonucleotides that range from 15 to 35 nucleotides in length but may range from 10 up to approximately 50 nucleotides in length. Binding typically reduces or inhibits the function of the target nucleic acid.
  • antisense oligonucleotides may block transcription when bound to genomic DNA, inhibit translation when bound to mRNA, and/or lead to degradation of the nucleic acid.
  • antisense oligonucleotides including stability, toxicity, tissue distribution, and cellular uptake and binding affinity may be altered through chemical modifications including (i) replacement of the phosphodiester backbone (e.g., peptide nucleic acid, phosphorothioate oligonucleotides, and phosphoramidate oligonucleotides), (ii) modification of the sugar base (e.g., 2'-O-propylribose and 2'-methoxyethoxyribose), and (iii) modification of the nucleoside (e.g., C-5 propynyl U, C-5 thiazole U, and phenoxazine C) [ Wagner, Nat.
  • the phosphodiester backbone e.g., peptide nucleic acid, phosphorothioate oligonucleotides, and phosphoramidate oligonucleotides
  • modification of the sugar base e.g., 2'-
  • the subunit or molecule is encoded by a gene within or linked to a schizophrenia susceptibility locus, or within which a functional mutation causing or contributing to susceptibility or development of schizophrenia may exist.
  • the biological system comprises a cell, and the contacting step comprises expressing the ribozyme in the cell.
  • the biological system comprises a subject, e.g., a mammalian subject such as a mouse or human, and the contacting step comprises administering the ribozyme to the subject or comprises expressing the ribozyme in the subject.
  • the expression may be inducible and/or tissue or cell-type specific according to certain embodiments of the invention.
  • the invention provides ribozymes designed to cleave transcripts encoding calcineurin subunits or calcineurin interacting molecules, or polymorphic variants thereof, as described above.
  • Exemplary doses include milligram or microgram amounts of the inventive composition per kilogram of subject or sample weight (e . g ., about 1 microgram per kilogram to about 500 milligrams per kilogram, about 100 micrograms per kilogram to about 5 milligrams per kilogram, or about 1 microgram per kilogram to about 50 micrograms per kilogram.) It is furthermore understood that appropriate doses may optionally be tailored to the particular recipient, for example, through administration of increasing doses until a preselected desired response is achieved.
  • any of the inventive compounds may be administered concurrently with an additional agent useful for treatment of schizophrenia.
  • Many such agents are known in the art and include a wide variety of typical and atypical anti-psychotic agents.
  • the compounds may be administered concurrently with compounds useful for ameliorating the side effects of anti-psychotic agents. See, for example, Hardman, J.G., et al., (eds.) Goodman & Gilman's The Pharmacological Basis of Therapeutics, 10th edition, McGraw Hill, 2001 , for discussion of numerous agents useful for the foregoing purposes.
  • the concurrently administered compounds may be administered to the subject separately or may be formulated together.
  • the methods may further comprise analyzying expression of the gene in normal subjects and in subjects affected with schizophrenia, which includes examining the mRNA abundance, size, and tissue expression pattern, examining the abundance, size, tissue expression pattern and/or activity of the encoded protein, etc.
  • CN mutants As CN mice were found to be hyperactive by several other indices of locomotor activity, the decreased number of light/dark transitions of CN mutant mice is particularly suggestive of increased fear or anxiety in CN mutant mice. In addition, despite their pronounced hyperactivity, CN mutants display a consistent, characteristic time course of locomotor activity, in which they are less active than control mice during the initial one or two minutes of the open field test ( Fig 1B ), the first object exploration trial ( Fig 1A ) and the social interaction test ( Fig 2D ). In light of the other two findings indicating increased anxiety-like behavior of CN mutant mice, it is probable that their lower initial activity reflects increased fearfulness towards novel stimuli/situations.
  • Reverse PCR primers contained 19-21 bp of homologous sequence fused on the 5' end to an 18 bp reverse universal sequencing tag: 5'-CAGGAAACAGCTATGACC-3' (SEQ ID NO: 2). This allowed all PCR fragments to be sequenced in both directions, using these two primers to prime all sequencing reactions. PCR reactions were performed using a programmable PCR tetrad machine (MJ Research, Cambridge MA). The majority of reactions were performed using OptiPrime 10x PCR buffer 6 (Stratagene, La Jolla, CA).
  • PCR amplification was as follows: an initial denaturation step at 94° C for 5 min, followed by 34 amplification cycles: 45 sec at 94° C; 60 sec at appropriate annealing temperature (usually 62.5° C): 60 sec elongation at 72° C, followed by a final extension step at 72° C for 7 min.
  • CA-2 and CA-9 are situated in the coding sequence, but neither creates a change in the amino acid sequence.
  • Four polymorphisms were identified in the PPP3CB gene, none of which are in the coding sequence.
  • Sixteen polymorphisms were found in the PPP3CC gene.
  • One of these, CC-5 is situated in exon 5 and results in a non-conservative change in the amino acid sequence of the encoded protein from a charged arginine residue at position 163 to a neutral glutamine residue.
  • the CC-5 polymorphism was found only in patient 15 among 12 patients. Since it creates a non-conservative amino acid change, it may represent a relatively rare functional mutation.
  • Six polymorphisms were identified in the CAMLG gene.
  • CG-2 is situated in the coding sequence and results in a conservative change from a valine to an isoleucine residue at position 78 of the protein. Further analysis found the CC-5 polymorphism in three of 210 tested patients and in none of 75 unaffected controls from the Coriell Cell Repository (the significance of this finding is unknown, since patient and control groups are not perfectly matched). Four polymorphisms were found in the FKBP 5 gene, none of which alter the coding sequence.
  • D8S136 Pulver et al., 1995, Brzustowicz et al., 1999; D8S1771: Blouin et al., 1998, Gurling et al., 2001; D8S1752: Blouin et al., 1998; D8S1715, D8S133: Kendler et al., 1996. Distances and positions in this figure are according to the Nov. 2002, human draft sequence.
  • Figure 6C shows haplotype distribution and transmission at the PPP3CC locus. Only four haplotypes with frequencies ⁇ 5% were observed in both US and SA samples and are shown here. The most common PPP3CC haplotype is consistently over-transmitted in both samples. T/nT: Transmitted/non-Transmitted.
  • Genotype method Genotyping PCR amplification Primers PPP3R1 R1P1 29 bp insertion R1-1 not listed not listed PCR-FLP R1P1aF, R1P1R PPP3R1 R1S1 SNP C/T R1-4 not listed not listed PCR-RFLP R1S1F, R1S1cR PPP3R1 R1-24 SNP A/G ----- rs1065248 hCV8833092 PCR-RFLP R1-24F, R1-24R PPP3R1 R1-28 SNP A/G ----- ----- hCV1282182 PCR-RFLP R1-28F, R1-28R PPP3R1 R1-S3 SNP T/C R1-18 rs3730335 ----- PCR-RFLP R1S3bF, R1S3R PPP3CA CAS6 SNP C/G ---- rs2850338 ----- PCR-RFLP CAS6-F, CAS6-R PPP3
  • Lane order of Figure 7A 1- 100 bp marker; 2- adult brain, primers 1; 3-adult brain, primers 2; 4- fetal brain primers 1; 5- fetal brain primers 2, 6- testis, primers 1; 7- testis, primers 2; 8- no DNA control, primers 1; 9- no DNA control, primers 2.
  • the products less than 100 bp in size are present in the no DNA control and are most likely primer- related amplification artifacts.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP10172269A 2002-03-26 2003-03-26 Cibles, procédés et réactifs pour le diagnostic et le traitement de la schizophrénie Withdrawn EP2270197A3 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36794402P 2002-03-26 2002-03-26
US45281303P 2003-03-07 2003-03-07
EP03728301A EP1578354A4 (fr) 2002-03-26 2003-03-26 Cibles, procedes et reactifs pour le diagnostic et le traitement de la schizophrenie

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP03728301.7 Division 2003-03-26

Publications (2)

Publication Number Publication Date
EP2270197A2 true EP2270197A2 (fr) 2011-01-05
EP2270197A3 EP2270197A3 (fr) 2011-02-16

Family

ID=28678204

Family Applications (2)

Application Number Title Priority Date Filing Date
EP03728301A Withdrawn EP1578354A4 (fr) 2002-03-26 2003-03-26 Cibles, procedes et reactifs pour le diagnostic et le traitement de la schizophrenie
EP10172269A Withdrawn EP2270197A3 (fr) 2002-03-26 2003-03-26 Cibles, procédés et réactifs pour le diagnostic et le traitement de la schizophrénie

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP03728301A Withdrawn EP1578354A4 (fr) 2002-03-26 2003-03-26 Cibles, procedes et reactifs pour le diagnostic et le traitement de la schizophrenie

Country Status (6)

Country Link
US (3) US7935500B2 (fr)
EP (2) EP1578354A4 (fr)
JP (2) JP4544865B2 (fr)
AU (1) AU2003233451A1 (fr)
CA (1) CA2481238A1 (fr)
WO (1) WO2003082210A2 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7820393B2 (en) * 1999-01-14 2010-10-26 Scantibodies Laboratory, Inc. Methods, kits and antibodies for detecting parathyroid hormone
US6689566B1 (en) * 1999-01-14 2004-02-10 Scantibodies Laboratory, Inc. Methods, kits, and antibodies for detecting parathyroid hormone
US6828097B1 (en) * 2000-05-16 2004-12-07 The Childrens Mercy Hospital Single copy genomic hybridization probes and method of generating same
JP4544865B2 (ja) 2002-03-26 2010-09-15 マサチューセッツ インスティテュート オブ テクノロジー 統合失調症の診断および治療のための標的、方法、ならびに試薬
WO2005004702A2 (fr) * 2003-06-30 2005-01-20 Massachusetts Institute Of Technology Genes egr en tant que cibles pour le diagnostic et le traitement de la schizophrenie
WO2005054500A1 (fr) * 2003-11-25 2005-06-16 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften Ev Fkbp51: cible destinee a un traitement antidepresseur
US20060210967A1 (en) * 2004-07-02 2006-09-21 Agan Brian K Re-sequencing pathogen microarray
EP1812594B1 (fr) * 2004-11-18 2013-01-09 Eppendorf Array Technologies Quantification en temps reel de cibles multiples sur un microreseau
AU2005321315A1 (en) * 2004-12-28 2006-07-06 Ares Trading S.A. Compositions and methods for treating schizophrenia and related disorders
US7897354B2 (en) * 2005-05-18 2011-03-01 Nuclea Biotechnologies, Inc. Kinase peptides and antibodies
WO2007046094A2 (fr) * 2005-10-17 2007-04-26 Hadasit Medical Research Services And Development Ltd. Genes et marqueurs associes a la schizophrenie
GB0524609D0 (en) * 2005-12-02 2006-01-11 Univ Cambridge Tech Methods of monitoring and diagnosing psychotic disorders and of identifying biomarkers for psychotic disorders
CA2537042A1 (fr) * 2006-02-21 2007-08-21 Soucy International Inc. Chenille poymerique
JP2009112266A (ja) * 2007-11-07 2009-05-28 Mitsubishi Tanabe Pharma Corp 精神神経疾患診断マーカ、診断方法、および治療薬評価方法
EP2570499A3 (fr) 2008-01-02 2013-04-03 Suregene Llc Marqueurs génétiques de maladie mentale
EP2581458A3 (fr) 2008-01-17 2013-07-17 Suregene LLC Marqueurs génétiques de maladie mentale
US8828657B2 (en) * 2008-02-14 2014-09-09 Decode Genetics Ehf. Susceptibility variants for lung cancer
US20100089287A1 (en) 2008-09-25 2010-04-15 Thames Shelby F Soy protein adhesive and uses thereof
US7972793B2 (en) 2009-11-04 2011-07-05 Suregene, Llc Methods and compositions for the treatment of psychotic disorders through the identification of the SULT4A1-1 haplotype
WO2012106407A2 (fr) 2011-02-01 2012-08-09 The University Of Vermont And State Agricultural College Procédés diagnostiques et thérapeutiques et produits liés aux troubles de l'anxiété
US20130090329A1 (en) 2011-10-07 2013-04-11 Suregene, Llc Methods and Compositions for the Treatment of Psychotic Disorders Through the Identification of the Olanzapine Poor Response Predictor Genetic Signature
JP5758479B2 (ja) * 2013-12-17 2015-08-05 学校法人藤田学園 精神神経疾患診断マーカ、診断方法、および治療薬評価方法
EP3143166A4 (fr) 2014-05-16 2018-04-18 University of Massachusetts Traitement de la leucémie myéloïde chronique (lmc)
CA2983041A1 (fr) 2015-04-16 2016-10-20 Alder Biopharmaceuticals, Inc. Utilisation d'anticorps anti-pacap et de leurs fragments de liaison a l'antigene pour le traitement, la prevention ou l'inhibition de la photophobie
EP3426686A4 (fr) 2016-04-15 2019-11-06 Alder Biopharmaceuticals, Inc. Anticorps anti-pacap humanisés et leurs utilisations
WO2018060766A2 (fr) * 2016-10-02 2018-04-05 Anavi Goffer Sharon Diagnostic de prédisposition génétique et traitement de troubles mentaux
US20210115419A1 (en) 2018-03-23 2021-04-22 Massachusetts Eye And Ear Infirmary CRISPR/Cas9-Mediated Exon-Skipping Approach for USH2A-Associated Usher Syndrome
MX2020010121A (es) 2018-03-27 2021-01-08 Univ Texas Compuestos con actividad antitumoral contra celulas de cancer que portan las mutaciones del exon 19 del receptor 2 del factor de crecimiento epidermico humano.
WO2020076723A1 (fr) 2018-10-08 2020-04-16 Revolution Medicines, Inc. Compositions d'inhibiteurs de shp2 destinées à être utilisées dans le traitement du cancer
AU2020242978A1 (en) 2019-03-19 2021-11-11 Cambridge Cognition Limited Method and uses of diagnosing and recommending treatment for a psychotic disorder
JP7556502B2 (ja) 2019-05-09 2024-09-26 フジフィルム セルラー ダイナミクス，インコーポレイテッド ヘパトサイトの作製方法
WO2021087458A2 (fr) 2019-11-02 2021-05-06 Board Of Regents, The University Of Texas System Ciblage de la dégradation des arnm non-sens pour activer la voie p53 pour le traitement du cancer
JP2023509701A (ja) 2020-01-07 2023-03-09 レヴォリューション・メディスンズ，インコーポレイテッド Ｓｈｐ２阻害剤投薬およびがんを処置する方法
WO2022060583A1 (fr) 2020-09-03 2022-03-24 Revolution Medicines, Inc. Utilisation d'inhibiteurs de sos1 pour traiter des malignités à mutations de shp2

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
WO1990015070A1 (fr) 1989-06-07 1990-12-13 Affymax Technologies N.V. Synthese a grande echelle de peptides immobilises
WO1992010092A1 (fr) 1990-12-06 1992-06-25 Affymax Technologies N.V. Synthese de polymeres immobilises sur tres grande echelle
US5288644A (en) 1990-04-04 1994-02-22 The Rockefeller University Instrument and method for the sequencing of genome
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
WO1995011995A1 (fr) 1993-10-26 1995-05-04 Affymax Technologies N.V. Reseaux de sondes d'acide nucleique sur des microplaquettes biologiques
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
WO1999064379A2 (fr) 1998-06-11 1999-12-16 President And Fellows Of Harvard College Synthese combinatoire biomimetique
US6248720B1 (en) 1996-07-03 2001-06-19 Brown University Research Foundation Method for gene therapy using nucleic acid loaded polymeric microparticles
US6316003B1 (en) 1989-12-21 2001-11-13 Whitehead Institute For Biomedical Research Tat-derived transport polypeptides
US6326166B1 (en) 1995-12-29 2001-12-04 Massachusetts Institute Of Technology Chimeric DNA-binding proteins
US6448443B1 (en) 1996-10-16 2002-09-10 President And Fellows Of Harvard College Synthesis of combinatorial libraries of compounds reminiscent of natural products
US20020165144A1 (en) 2000-02-28 2002-11-07 Decode Genetics Ehf, Iceland Human schizophrenia gene

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1103699A (en) * 1997-10-17 1999-05-10 Rockefeller University, The Use of an inhibitor of the dephosphorylation of darpp-32 for treating schizophrenia
US6013621A (en) * 1997-10-17 2000-01-11 The Rockfeller University Method of treating psychosis and/or hyperactivity
AU2002324666B2 (en) * 2001-08-10 2007-10-11 The Rockefeller University Compostions and methods for modulation of DARPP-32 phosphorylation
US20060241042A1 (en) * 2002-03-22 2006-10-26 National Institute Of Agrobiological Sciences Calcineurin activators
JP4544865B2 (ja) 2002-03-26 2010-09-15 マサチューセッツ インスティテュート オブ テクノロジー 統合失調症の診断および治療のための標的、方法、ならびに試薬
AU2003250033A1 (en) * 2002-07-11 2004-02-02 Novartis Ag Genes associated with schizophrenia, adhd and bipolar disorders

Patent Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683202B1 (fr) 1985-03-28 1990-11-27 Cetus Corp
WO1990015070A1 (fr) 1989-06-07 1990-12-13 Affymax Technologies N.V. Synthese a grande echelle de peptides immobilises
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US6316003B1 (en) 1989-12-21 2001-11-13 Whitehead Institute For Biomedical Research Tat-derived transport polypeptides
US5288644A (en) 1990-04-04 1994-02-22 The Rockefeller University Instrument and method for the sequencing of genome
WO1992010092A1 (fr) 1990-12-06 1992-06-25 Affymax Technologies N.V. Synthese de polymeres immobilises sur tres grande echelle
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
WO1995011995A1 (fr) 1993-10-26 1995-05-04 Affymax Technologies N.V. Reseaux de sondes d'acide nucleique sur des microplaquettes biologiques
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US6326166B1 (en) 1995-12-29 2001-12-04 Massachusetts Institute Of Technology Chimeric DNA-binding proteins
US6248720B1 (en) 1996-07-03 2001-06-19 Brown University Research Foundation Method for gene therapy using nucleic acid loaded polymeric microparticles
US6448443B1 (en) 1996-10-16 2002-09-10 President And Fellows Of Harvard College Synthesis of combinatorial libraries of compounds reminiscent of natural products
WO1999064379A2 (fr) 1998-06-11 1999-12-16 President And Fellows Of Harvard College Synthese combinatoire biomimetique
US20020165144A1 (en) 2000-02-28 2002-11-07 Decode Genetics Ehf, Iceland Human schizophrenia gene

Non-Patent Citations (231)

* Cited by examiner, † Cited by third party
Title
"schizophrenia susceptibility locus in families from Palau, Micronesia", MOL PSYCHIATRY, vol. 3, 1998, pages 521 - 7
ALBERTS, A.S. ET AL.: "Expression of a peptide inhibitor of protein phosphatase 1 increases phosphorylation and activity of CREB in NIH 3T3 fibroblasts", MOL CELL BIOL, vol. 14, no. 7, 1994, pages 4398 - 407
ALDERBOM, A. ET AL., GENOME RESEARCH, vol. 10, no. 8, 2000, pages 1249 - 1258
ALEXANDER REUTER, JUN MI, INKEN SEHRSAM, ALBERT C. LUDOLPH AND HELGE VÖLKEL: "A novel calcineurin splice variant that modifies calcineurin activity", 1 January 2001 (2001-01-01), XP055011624, Retrieved from the Internet <URL:http://onlinelibrary.wiley.com/store/10.1046/j.0014-2956.2001.02551.x/asset/j.0014-2956.2001.02551.x.pdf?v=1&t=gus70kci&s=c0d7b34d822cf45c160f84a84e999fd6a0426b23> [retrieved on 20111109] *
ALTCHUL, SF; GISH, W, METHODS IN ENZYMOLOGY
ALTSCHUL, SF ET AL.: "Basic local alignment search tool", J. MOL. BIOL., vol. 215, no. 3, 1990, pages 403 - 410
ALTSCHUL, SF ET AL.: "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", NUCLEIC ACIDS RES., vol. 25, 1997, pages 3389 - 3402
AMITAL, H.; Y. SHOENFELD: "Autoimmunity and schizophrenia: an epiphenomenon or an etiology?", ISR J MED SCI, vol. 29, no. 9, 1993, pages 593 - 7
BAILER, U.; LEISCH, F.; MESZAROS, K.; LENZINGER, E.; WILLINGER, U.; STROBL, R.; GEBHARDT, C.; GERHARD, E.; FUCHS, K.; SIEGHART, W.: "Genome scan for susceptibility loci for schizophrenia", NEUROPSYCHOBIOLOGY, vol. 42, 2000, pages 175 - 82
BAKER; MONIA, BIOCHIM. BIOPHYS. ACTA, vol. 1489, 1999, pages 3
BALSCHUN, D.; WOLFER, D.P.; BERTOCCHINI, F.; BARONE, V.; CONTI, A.; ZUSCHRATTER, W.; MISSIAEN, L.; LIPP, H.P.; FREY, J.U.; SORRENT: "Deletion of the ryanodine receptor type 3 (RyR3) impairs forms of synaptic plasticity and spatial learning", EMBO J, vol. 18, 1999, pages 5264 - 73
BANERJI ET AL., CELL, vol. 33, 1983, pages 729
BAUGHMAN, G. ET AL.: "FKBP51, a novel T-cell-specific immunophilin capable of calcineurin inhibition", MOL CELL BIOL, vol. 15, no. 8, 1995, pages 4395 - 402
BAUGHMAN, G. ET AL.: "Tissue distribution and abundance of human FKBP51, and FK506-binding protein that can mediate calcineurin inhibition", BIOCHEM BIOPHYS RES COMMUN, vol. 232, no. 2, 1997, pages 437 - 43
BAUMGRASS, R. ET AL.: "Reversible inhibition of calcineurin by the polyplzenolic aldehyde gossypol", J BIOL CHEM, vol. 276, no. 51, 2001, pages 47914 - 21
BAUMGRASS, R. ET AL.: "Reversible inhibition of calcineurin by thepolyphetiolic aldelzyde gossypol", J BIOL CHEM, vol. 276, no. 51, 2001, pages 47914 - 21
BERNSTEIN ET AL., NATURE, vol. 409, 2001, pages 363
BLOUIN, J.L.; DOMBROSKI, B.A.; NATH, S.K.; LASSETER, V.K.; WOLYNIEC, P.S.; NESTADT, G.; THOMQUIST, M.; ULLRICH, G.; MCGRATH, J.; K: "Schizophrenia susceptibility loci on chromosomes 13q32 and 8p21", NAT GENET, vol. 20, 1998, pages 70 - 3
BLOUIN, J.L.; DOMBROSKI, B.A.; NATH, S.K.; LASSETER, V.K.; WOLYNIEC, P.S.; NESTADT, G.; THOMQUIST, M.; ULLRZCH, G.; MCGRATH, J.; K: "Schizophrenia susceptibility loci on chromosomes", NAT GENET, vol. 20, 1998, pages 70 - 3
BOCKAMP, E. ET AL., PHYSIOL GENOMICS, vol. 11, no. 3, 2002, pages 115 - 32
BOSS, V.; D.J. TALPADE; T.J. MURPHY: "Induction of NFAT-mediated transcription by Gq-coupled receptors in lymphoid and noti-lyniphoid cells.", J BIOL CHEM, vol. 271, no. 18, 1996, pages 10429 - 32
BOSS, V.; D.J. TALPADE; T.J. MURPHY: "Induction ofNFAT-mediated transcription by Gq-coupled receptors in lymphoid and non-lymphoid cells", J BIOL CHEM, vol. 271, no. 18, 1996, pages 10429 - 32
BOUTE N; JOCKERS R; ISSAD T., TRENDS PHARMACOL SCI., vol. 23, no. 8, August 2002 (2002-08-01), pages 351 - 4
BOUTE, N. ET AL., TRENDS IN PHARMACOL SCI, vol. 23, no. 8, 2002, pages 351 - 4
BRAM, R.J.; G.R. CRABTREE: "Calcium signalling in T cells stimulated by a cyclophilin B-binding protein", NATURE, vol. 371, no. 6495, 1994, pages 355 - 8
BRUMMELKAMP, T. ET AL., SCIENCE, vol. 296, 2002, pages 550 - 553
BRZUSTOWICZ, L.M.; HODGKINSON, K.A.; CHOW, E.W.; HONER, W.G.; BASSETT, A.S.: "Location of a major susceptibility locus for familial schizophrenia on chromosome 1q21-q22", SCIENCE, vol. 288, 2000, pages 678 - 82
BYRNE ET AL., PROC. NATL. ACAD. SCI. USA, vol. 86, 1989, pages 5473
CALAME ET AL., ADV. IMMUNOL., vol. 43, 1988, pages 235
CAMERON, A. M. ET AL., CELL, vol. 83, 1995, pages 463 - 72
CAMERON, A.M. ET AL.: "Calcineurin associated mith the inositol 1,4,5-trisplzosphate receptor- FKBP12 complex modulates Ca2+ flux", CELL, vol. 83, no. 3, 1995, pages 463 - 72
CAMP, N.J.; NEUHAUSEN, S.L.; TIOBECH, J.; POLLOI, A.; COON, H.; MYLES-WORSLEY, M.: "Genomewide multipoint linkage analysis of seven extended Palauan pedigrees with schizophrenia, by a Markov-chain Monte Carlo method", AM J HUM GENET, vol. 69, 2001, pages 1278 - 89
CAMP, N.J.; NEUHAUSEN, S.L.; TIOBECH, J.; POLLOI, A.; COON, H.; MYLES-WORSLEY, M.: "Genomewide multipoint linkage analysis of seven extended Palauan pedigrees with schizophrenia, by a Markov-chain Monte Carlo method", AM JHUM GENET, vol. 69, 2001, pages 1278 - 89
CAMPES ET AL., GENES DEV., vol. 3, 1989, pages 537
CARDON, L.; BELL, J., NATURE REVIEWS GENETICS, vol. 2, 2001, pages 91 - 99
CARLSSON, A. ET AL., ANNU REV PHARMACOL TOXICOL, vol. 41, 2001, pages 237 - 60
CHANG, H. ET AL., NATURE, vol. 376, 1995, pages 686 - 690
CHEN, X. ET AL., GENOME RESEARCH, vol. 9, no. 5, 1999, pages 492 - 498
CHOWDARI, K.V.; XU, K.; ZHANG, F.; MA, C.; LI, T.; XIE, B.Y.; WOOD, J.; TRUCCO, M.; TSOI, W.F.; SAHA, N.: "Immune related genetic polymorphisms and schizophrenia among the Chinese", HUM IMMUNOL, vol. 62, 2001, pages 714 - 24
CHOWDARI, K.V.; XU, K.; ZHANG, F.; MA, C.; LI, T.; XIE, B.Y.; WOOD, J.; TRUCCO, M.; TSOI, W.F.; SAHA, N.: "Immune related genetic polymorphisms and schizophrenia among the Chinese", HUM IMRRZURXOL, vol. 62, 2001, pages 714 - 24
CHUMAKOV I; BLUMENFELD M; GUERASSIMENKO O; CAVAREC L; PALICIO M; ABDERRAHIM H; BOUGUELERET L; BARRY C; TANAKA H, LA ROSA P; PUECH, PROC NATL ACAD SCI USA., vol. 99, no. 21, 15 October 2002 (2002-10-15), pages 13675 - 80
CHURCH; GILBERT, PROC. NATL. ACAD. SCI. USA, vol. 81, 1988, pages 1991 - 1995
CLAYTON, D., AM J HUM GENET., vol. 65, no. 4, October 1999 (1999-10-01), pages 1170 - 7
COGHLAN, V.M. ET AL.: "Association of protein kinase A and protein phosphatase 2B with a common anchoring protein", SCIENCE, vol. 267, no. 5194, 1995, pages 108 - 11
COON, H.; MYLES-WORSLEY, M.; TIOBECH, J.; HOFF, M.; ROSENTHAL, J.; BENNETT, P.; REIMHERR, F.; WENDER, P.; DALE, P.; POLLOI, A., EVIDENCE FOR A CHROMOSOME, vol. 2, pages 13 - 14
COTTEN; BIMSTIEL: "Ribozyme mediated destruction of RNA in vivo", EMBO J., vol. 8, 1989, pages 3861 - 3866
COTTEN; BIRNSTIEL, EMBO J., vol. 8, 1989, pages 3861 - 3866
COTTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1985, pages 4397 - 4401
CRABTREE, G. R.; OLSON, E. N., CELL, vol. 109, 2002, pages 67 - 79
CRABTREE, G., J. BIOL. CHEM., vol. 276, no. 4, 2001, pages 2313 - 2316
CRADDOCK, N.; LENDON, C.: "Chromosome Workshop: chromosomes 11, 14, and 15", AIN JMED GENET, vol. 88, 1999, pages 244 - 54
CRADDOCK, N.; LENDON, C.: "Chromosome Workshop: chromosomes 11, 14, and 15", AM JMED GENET, vol. 88, 1999, pages 244 - 54
CRAWLEY, J.N: "Exploratory behavior models of anxiety in mice", NEUROSCI BIOBEHAV REV, vol. 9, 1985, pages 37 - 44
CROWE, R. R.; VIELAND, V., AM J. MED GENET, vol. 88, no. 3, 18 June 1999 (1999-06-18), pages 229 - 32
CROWE, R.R.; VIELAND, V.: "Report of the Chromosome 5 Workshop of the Sixth World Congress on Psychiatric Genetics", AM JMED GENET, vol. 88, 1999, pages 229 - 32
CZERNIK, A.J. ET AL.: "Production ofphosphorylation state-specific antibodies", METHODS ENZYMOL, vol. 201, 1991, pages 264 - 83
DAY, M.; OLSON, P. A.; PLATZER, J.; STRIESSNIG, J.; SURMEIER, D. J., J NEUROPHYSIOL, vol. 87, 2002, pages 2490 - 504
DENHARDT, ANNALS N Y ACAD. SCI., vol. 660, 1992, pages 70
FANGER, C. ET AL., J. CELL. BIOL, vol. 131, 1995, pages 655 - 667
FARAONE, S.V.; MATISE, T.; SVRAKIC, D.; PEPPLE, J.; MALASPINA, D.; SUAREZ, B.; HAMPE, C.; ZAMBUTO, C.T.; SCHMITT, K.; MEYER, J.: "Genome scan of European-American schizophrenia pedigrees: results of the NIMH Genetics Initiative and Millennium Consortium", AM J MED GENET, vol. 81, 1998, pages 290 - 5
FARAONE, S.V.; MATISE, T.; SVRAKIC, D.; PEPPLE, J.; MALASPINA, D.; SUAREZ, B.; HAMPE, C.; ZAMBUTO, C.T.; SCHMITT, K.; MEYER, J.: "Genome scan of European-American schizophrenia pedigrees: results of the NIMH Genetics Initiative and Millennium Consortium", AM JMED GENET, vol. 81, 1998, pages 290 - 5
FLANAGAN, W.M., NATURE, vol. 352, 1991, pages 803 - 7
FLAVELL ET AL., CELL, vol. 15, 1978, pages 25
FLOYD CD; LEBLANC C; WHITTAKER M, PROG MED CHEM, vol. 36, 1999, pages 91 - 168
FODOR ET AL., SCIENCE, vol. 251, 1991, pages 767 - 777
FREEDMAN, R.; LEONARD, S.; OLINCY, A.; KAUFINANN, C.A.; MALASPINA, D.; CLONINGER, C.R.; SVRAKIC, D.; FARAONE, S.V.; TSUANG, M.T.: "Evidence for the multigenic inheritance of schizophrenia", AM JMED GENET, vol. 105, 2001, pages 794 - 800
FREEDMAN, R.; LEONARD, S.; OLINCY, A.; KAUFMANN, C.A.; MALASPINA, D.; CLONINGER, C.R.; SVRAKIC, D.; FARAONE, S.V.; TSUANG, M.T.: "Evidence for the multigenic inheritance of schizophrenia", AM J MED GENET, vol. 105, 2001, pages 794 - 800
FRENCH; GERDES, CURR. OPIN. MICROBIOL., vol. 3, 2000, pages 159
FREY, N.; J.A. RICHARDSON; E.N. OLSON: "Calsarcins, a novel family of sarconieric calcineurin-binding proteins", PROC NATL ACAD SCI U S A, vol. 97, no. 26, 2000, pages 14632 - 7
FUTATSUGI, A.; KATO, K.; OGURA, H.; LI, S.T.; NAGATA, E.; KUWAJIMA, G.; TANAKA, K.; ITOHARA, S.; MIKOSHIBA, K.: "Facilitation of NMDAR-independent LTP and spatial learning in mutant mice lacking ryanodine receptor type 3", NEURON, vol. 24, 1999, pages 701 - 13
GAINETDINOV ET AL.: "Genetic animal models: focus on schizophrenia", TRENDS IN NEUROSCIENCES, vol. 24, no. 9, September 2001 (2001-09-01)
GANGULI, R. ET AL.: "Autoimmunity in schizophrenia: a review ofrecent findings", ANN MED, vol. 25, no. 5, 1993, pages 489 - 96
GANGULI, R., J.S. BRAR; B.S. RABIN: "Immune abnormalities in schizophrenia: evidence for the autoimmune hypothesis", HARV REV PSYCHIATRY, vol. 2, no. 2, 1994, pages 70 - 83
GEEVER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 78, 1981, pages 5081
GENAZZANI, A. A.; CARAFOLI, E.; GUERINI, D., PROC NATL ACAD SCI USA, vol. 96, 1999, pages 5797 - 801
GENAZZANI, A.A.; CARAFOLI, E.; GUERINI, D.: "Calcineurin controls inositol 1,4,5-trisphosphate type 1 receptor expression in neurons", PROC NATL ACAD SCI USA, vol. 96, 1999, pages 5797 - 801
GENAZZANI, A.A.; E. CARAFOLI; D. GUERINI: "Calcineurin controls inositol l,4,5-trisphosphate type 1 receptor expression in neurons", PROC NATL ACAD SCI U S A, vol. 96, no. 10, 1999, pages 5797 - 801
GOODMAN, A.B.: "Elevated risks for amyotrophic lateral sclerosis and blood disorders in Ashkenazi schizophrenic pedigrees suggest new candidate genes in schizophrenia", AM J MED GENET, vol. 54, 1994, pages 271 - 8
GRAEF, I.A.; F. CHEN; G.R. CRABTREE: "NFAT signaling in vertebrate development", CURR OPIN GENET DEV, vol. 11, no. 5, 2001, pages 505 - 12
GREENGARD, P., SCIENCE, vol. 294, 2001, pages 1024 - 30
GRIFFITH, JP ET AL.: "X-ray structure of calcineurin inhibited by the immunophilin-immunosuppressant FKBP12-FK506 complex", CELL, vol. 82, no. 3, 11 August 1995 (1995-08-11), pages 507 - 22
GRISHOK, A. ET AL., CELL, vol. 106, 2001, pages 23 - 24
GUATELLI ET AL., PROC. NAT. ACAD. SCI. USA, vol. 87, 1990, pages 1874
GURLING, H.M.; KALSI, G.; BRYNJOLFSON, J.; SIGMUNDSSON, T.; SHERRINGTON, R.; MANKOO, B.S.; READ, T.; MURPHY, P.; BLAVERI, E.; MCQU: "Genomewide genetic linkage analysis confirms the presence of susceptibility loci for schizophrenia, on chromosomes lq32.2, 5q33.2, and 8p21-22 and provides support for linkage to schizophrenia, on chromosomes 11q23.3-24 and 20q12.1-11.23", AIYI J HUM GENET, vol. 68, 2001, pages 661 - 73
GURLING, H.M.; KALSI, G.; BRYNJOLFSON, J.; SIGMUNDSSON, T.; SHERRINGTON, R.; MANKOO, B.S.; READ, T.; MURPHY, P.; BLAVERI, E.; MCQU: "Genomewide genetic linkage analysis confirms the presence of susceptibility loci for schizophrenia, on chromosomes lq32.2, 5q33.2, and 8p21-22 and provides support for linkage to schizophrenia, on chromosomes 11q23.3-24 and 20q12.1-11.23", AM J HUM GENET, vol. 68, 2001, pages 661 - 73
HASHIMOTO, H. ET AL.: "Altered psychonzotor behaviors in mice lacking pituitary adenylate cyclase-activating polypeptide (PACAP)", PROC NATL ACAD SCI U S A, vol. 98, no. 23, 2001, pages 13355 - 60
HASUWA, H. ET AL., FEBS LETT, vol. 532, no. 1-2, 4 December 2002 (2002-12-04), pages 227 - 30
HAUCKE, V., NAT NEUROSCI, vol. 3, 2000, pages 1230 - 2
HODGKISS, J.P.; J.S. KELLY: "Only 'de novo' long-term depression (LTD) in the rat hippocampus in vitro is blocked by the same low concentration of FK506 that blocks LTD in the visual cortex", BRAIN RES, vol. 705, no. 1-2, 1995, pages 241 - 46
HORSLEY, V.; G.K. PAVLATH: "Nfat: ubiquitous regulator of cell differentiation and adaptation", J CELL BIOL, vol. 156, no. 5, 2002, pages 771 - 4
HUTVAGNER, G. ET AL., SCIENCE, vol. 293, 2001, pages 834 - 838
IKEGAMI, S. ET AL.: "A facilitatory effect on the induction of long-term potentiation in vivo by chronic administration of antisense oligodeoxynucleotides against catalytic subunits of calcineurin", BRAIN RES MOL BRAIN RES, vol. 41, no. 1-2, 1996, pages 183 - 91
ISAAC, J.: "Protein Phosphatase 1 and LTD. Synapses Are the Arcllitects of Depression.", NEURON, vol. 32, no. 6, 2001, pages 963 - 6
JAVITT, D; ZUKIN, R., AM JPSYCHIATRY, vol. 148, no. 10, October 1991 (1991-10-01), pages 1301 - 8
JORDE, L.B., GENOME RESEARCH, vol. 10, 2000, pages 1435 - 1444
KAO, P.N. ET AL.: "Cloning and expression of cyelospor-in A- and FK506-sensitive nuclear factor of activated T-cells: NF45 and NF90", J BIOL CHEM, vol. 269, no. 32, 1994, pages 20691 - 9
KARAYIORGOU, M.; GOGOS, J. A., NEURON, vol. 19, 1997, pages 967 - 79
KARAYIORGOU, M.; GOGOS, J.A.: "A turning point in schizophrenia genetics", NEURON, vol. 19, 1997, pages 967 - 79
KARAYIORGOU, M.; MORRIS, M.A.; MORROW, B.; SHPRINTZEN, R.J.; GOLDBERG, R.; BORROW, J.; GOS, A.; NESTADT, G.; WOLYNIEC, P.S.; LASSE: "Schizophrenia susceptibility associated with interstitial deletions of chromosome 22q11", PROC NATL ACAD SCI U S A, vol. 92, 1995, pages 7612 - 6
KASHISHIAN, A. ET AL.: "AKAP79 inhibits calcineurin through a site distinct from the immunophilin-binding region", J BIOL CHEM, vol. 273, no. 42, 1998, pages 27412 - 9
KATO, K.: "The role of calcineurin on the induction of synaptic plasticity", NIHON SHINKEI SEISHIN YAKURIGAKU ZASSHI, vol. 20, no. 5, 2000, pages 189 - 98
KENDLER, K.S.; MACLEAN, C.J.; O'NEILL, F.A.; BURKE, J.; MURPHY, B.; DUKE, F.; SHINKWIN, R.; EASTER, S.M.; WEBB, B.T.; ZHANG, J.: "Evidence for a schizophrenia vulnerability locus on chromosome 8p in the Irish Study of High-Density Schizophrenia Families", AM J PSYCHIATRY, vol. 153, 1996, pages 1534 - 40
KENNEDY, J.L.; BASILE, V.S.; MACCIARDI, F.M.: "Chromosome 4 Workshop Summary: Sixth World Congress on Psychiatric Genetics", AM JMED GENET, vol. 88, 1999, pages 224 - 8
KESSEL ET AL., SCIENCE, vol. 249, 1990, pages 374
KETTING, R. ET AL., GENES DEV., vol. 15, pages 2654 - 2659
KIRCH, D.G: "Infection and autoimnzunity as etiologic factors in schizophrenia: a review and reappraisal", SCHIZOPHR BULL, vol. 19, no. 2, 1993, pages 355 - 70
KISSINGER, CR ET AL.: "Crystal structures of human calcineurin and the human FKBP12-FK506-calcineurin complex", NATURE, vol. 378, no. 6557, 1995, pages 641 - 4
KLAUCK, T.M. ET AL.: "Coordination of three signaling ettzynes by AKAP79, a mammalian scaffold protein", SCIENCE, vol. 271, no. 5255, 1996, pages 1589 - 92
KLEE, C. B.; REN, H.; WANG, X., JBIOL CHEM, vol. 273, 1998, pages 13367 - 70
KLINGER, M. ET AL.: "Suramin and the suramin analogue NF307 discriminate among calmodulin- binding sites", BIOCHEM J, vol. 355, 2001, pages 827 - 33
KOLANUS, W., CURR TOP MICROBIOL IMMURTOL, vol. 243, 1999, pages 37 - 54
KOUZU, Y.; MORIYA, T.; TAKESHIMA, H.; YOSHIOKA, T.; SHIBATA, S.: "Mutant mice lacking ryanodine receptor type 3 exhibit deficits of contextual fear conditioning and activation of calcium/calmodulin- dependent protein kinase II in the hippocampus", BRAIN RES MOL BRAIN RES, vol. 76, 2000, pages 142 - 50
KRUGLYAK, L.; LANDER, E., AM. J. HUM. GENET., vol. 56, 1995, pages 1212 - 1223
KWAN, K.: "Conditional alleles in mice: practical considerations for tissue-specific knockouts.", GENESIS, vol. 32, no. 2, 2002, pages 49 - 62
KWOH ET AL., PROC. NATL. ACAD. SCI. USA, vol. 86, 1989, pages 1173
LAGOS-QUINTANA, M. ET AL., SCIENCE, vol. 294, 2001, pages 853 - 858
LAI, M.M. ET AL., JBIOL CHEM, vol. 274, 1999, pages 25963 - 6
LAI, M.M. ET AL.: "Cain, a novel physiologic protein inhibitor of calcineurin", J BIOL CHEM, vol. 273, no. 29, 1998, pages 18325 - 31
LAI, M.M.; BURNETT, P.E.; WOLOSKER, H.; BLACKSHAW, S.; SNYDER, S.H.: "Cain, a novel physiologic protein inhibitor of calcineurin", JBIOL CHEM, vol. 273, 1998, pages 18325 - 31
LANDEGREN ET AL., SCIENCE, vol. 241, 1988, pages 1077
LEE, H.W. ET AL.: "Pituitary adenylate cyclase-activating polypeptide regulation of vasoactive intestinal polypeptide transcription requires Ca2+ influx and activation of the setinelthreonine phosphatase calcineurin.", J NEUROCHEM, vol. 73, no. 4, 1999, pages 1769 - 72
LEFEBVRE, P. ET AL.: "Protein phosphatases 1 and 2A regulate the transcriptional and DNA binding activities of retinoic acid receptors", J BIOL CHEM, vol. 270, no. 18, 1995, pages 10806 - 16
LEVINSON, D.F.; MAHTANI, M.M.; NANCARROW, D.J.; BROWN, D.M.; KRUGLYAK, L.; KIRBY, A.; HAYWARD, N.K.; CROWE, R.R.; ANDREASEN, N.C.;: "Genome scan of schizophrenia", ANT J PSYCHIATRY, vol. 155, 1998, pages 741 - 50
LEVINSON, D.F.; MAHTANI, M.M.; NANCARROW, D.J.; BROWN, D.M.; KRUGLYAK, L.; KIRBY, A.; HAYWARD, N.K.; CROWE, RR; ANDREASEN, N.C.; B: "Genome scan of schizophrenia", AM J PSYCHIATLY, vol. 155, 1998, pages 741 - 50
LEWANDOWSKI, M.: "Conditional control of gene expression in the mouse", NAT. REV.. GENET., vol. 2, no. 10, 2001, pages 743 - 55
LEWIS, D. A.; LIEBERMAN, J. A., NEURON, vol. 28, 2000, pages 325 - 3
LEWONTIN RC: "On measures of gametic disequilibrium", GENETICS, vol. 120, 1988, pages 849 - 852
LI, H.; STARK, G.: "NFKB-dependent signaling pathways", EXP. HEMATOL., vol. 30, 2002, pages 285 - 296
LI, T.K. ET AL.: "Calcium- and FK506-independent interaction between the immunophilin FKBP51 and calcineurin", J CELL BIOCHEM, vol. 84, no. 3, 2002, pages 460 - 71
LIN, X. ET AL.: "Inhibition of calcineurin phosphatase activity by a calcineurin B homologous protein", J BIOL CHEM, vol. 274, no. 5 1, 1999, pages 36125 - 3 1
LIN, X.; SIKKINK, R.A.; RUSNAK, F.; BARBER, D.L.: "Inhibition of calcineurin phosphatase activity by a calcineurin B homologous protein", J BIOL CHEM, vol. 274, 1999, pages 36125 - 31
LIU H; ABECASIS GR; HEATH SC; KNOWLES A; DEMARS S; CHEN YJ; ROOS JL; RAPOPORT JL; GOGOS JA; KARAYIORGOU M., PROC NATL ACAD SCI U S A., vol. 99, no. 26, 24 December 2002 (2002-12-24), pages 16859 - 64
LIU H; HEATH SC; SOBIN C; ROOS JL; GALKE BL; BLUNDELL ML; LENANE M; ROBERTSON B; WIJSMAN EM; RAPOPORT JL, PROC NATL ACAD SCI U S A., vol. 99, no. 6, 19 March 2002 (2002-03-19), pages 3717 - 22
LIU, J. ET AL., CELL, vol. 66, 1991, pages 807 - 15
M. J. MCPHERSON; MATTILA ET AL., NUCLEIC ACIDS RES., vol. 19, 1991, pages 4967
M.K., M. TORRINGTON; C.S., B.R.; S.C.H., M.L.B.; H. PRETORIUS; S. LAY; J.A.G.; J.L.R.: "Probands in both samples met lifetime criteria for Diagnostic and Statistical Manual of Mental Disorders, 4th Ed. (DSM-IV) (American Psychiatric Association.", DIAGNOSTIC AND STATISTICAL MANUAL (AM. PSYCHIATRIC ASSOC., WASHINGTON, DC), 1994
MANFROID, I.; J.A. MARTIAL; M. MULLER: "Inhibition ofprotein phosphatase PPI in GH3B6, but not in GH3 cells, activates the MEKlERK/c-fos pathway and the human prolactin promoter, involving the coactivator CPBlp300", MOL ENDOCRINOL, vol. 15, no. 4, 2001, pages 625 - 37
MARCOULATOS, P. ET AL.: "Mapping interleukin enhancer binding factor 2 gene (ILF2) to human chromosome 1 (Iqll-qter and lpll-pl2) bypolymerase chain reaction amplification of lzunzari-rodent somatic cell hybrid DNA templates", J INTERFERON CYTOKINE RES, vol. 16, no. 12, 1996, pages 1035 - 8
MCINNES, L.A.; SERVICE, S.K.; REUS, V.I.; BARNES, G.; CHARLAT, 0.; JAWAHAR, S.; LEWITZKY, S.; YANG, Q.; DUONG, Q.; SPESNY, M.: "Fine-scale mapping of a locus for severe bipolar mood disorder on chromosome 18p11.3 in the Costa Rican population", PROC NATL ACAD SCI U S A, vol. 98, 2001, pages 11485 - 90
MCMANUS, M.T. ET AL., RNA, vol. 8, 2002, pages 842 - 850
MISRA, U.K.; G. GAWDI; S.V. PIZZO: "Chloroquine, quinine and quinidine inhibit calcium release fi-om macrophage intracellular stores by blocking inositol 1,4,5- trisphosphate binding to its receptor", J CELL BIOCHEM, vol. 64, no. 2, 1997, pages 225 - 32
MISRA, U.K.; G. GAWDI; S.V. PIZZO: "Cyclosporin A inhibits inositol 1,4,5-trisphosphate binding to its receptors and release of calcium from intracellular stores in peritoneal macrophages", J IMMUNOL, vol. 161, no. 11, 1998, pages 6122 - 7
MIYAKAWA, T.; YAMADA, M.; DUTTAROY, A.; WESS, J.: "Hyperactivity and intact hippocampus-dependent learning in mice lacking the Ml muscarinic acetylcholine receptor", JNEUROSCI, vol. 21, 2001, pages 5239 - 50
MOHN, A.R. ET AL.: "Mice with reduced NMDA receptor expression display behaviors related to schizophrenia", CELL, vol. 98, no. 4, 1999, pages 427 - 36
MONDRAGON, A. ET AL., BIOCHEMISTRY, vol. 36, no. 16, 1997, pages 4934 - 42
MONDRAGON, A; GRIFFITH, E. C; SUN, L; XIONG, F; ARMSTRONG, C; LIU, J. O., BIOCHEINISTRY, vol. 36, no. 16, 22 April 1997 (1997-04-22), pages 4934 - 42
MULKEY, R. ET AL., NATURE, vol. 369, 1994, pages 486 - 8
MULKEY, R.M. ET AL.: "Involvement of a calcineurin/inhibitor-1 phosphatase cascade in hippocampal long-term depression", NATURE, vol. 369, no. 6480, 1994, pages 486 - 8
MYERS, R. M. ET AL., SCIENCE, vol. 230, 1985, pages 1242
NEILSEN, CURR. OPIN. BIOTECH., vol. 10, 1999, pages 71
NELLEN, TRENDS BIOCHEM. SCI., vol. 18, 1993, pages 419
NICOLSON, R. ET AL., AIN. J PSYCHIATRY, vol. 157, 2000, pages 794 - 800
NIELSEN ET AL., SCIENCE, vol. 254, 1991, pages 1497 - 1500
NOWOTNY, P. ET AL., CURR. OP. NEUROBIOL., vol. 11, 2001, pages 637 - 641
NOY, S.; A. ACHIRON; N. LAOR: "Schizophrenia and autoimmunity--a possible etiological mechanism?", NEUROPSYCHOBIOLOGY, vol. 30, no. 4, 1994, pages 157 - 9
NUMBERGER, J. I. ET AL., ARCH. GEN. PSYCHIATRY, vol. 51, 1994, pages 849 - 859
ORITA, M. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 86, 1989, pages 2766 - 2770
OTTO, C. ET AL.: "Altered emotional behavior in PACAP-type-l-receptor-deficient mice", BRAIN RES MOL BRAIN RES, vol. 92, no. 1-2, 2001, pages 78 - 84
PADDISON, P. ET AL., GENES AND DEV., vol. 16, 2002, pages 948 - 958
PALAU; MICRONESIA, MOL PSYCHIATRY, vol. 3, 1998, pages 521 - 7
PASQUINELLI, A., TRENDS IN GENETICS, vol. 18, no. 4, 2002, pages 171 - 173
PAUL, C. ET AL., NAT. BIOTECH., vol. 20, 2002, pages 505 - 508
PAUNIO, T.; EKELUND, J.; VARILO, T.; PARKER, A.; HOVATTA, I.; TURUNEN, J.A.; RINARD, K.; FOTI, A.; TERWILLIGER, J.D.; JUVONEN, H.: "Genome-wide scan in a nationwide study sample of schizophrenia families in Finland reveals susceptibility loci on chromosomes 2q and 5q", HUM MOL GENET, vol. 10, 2001, pages 3037 - 48
PLYTE, S. ET AL.: "Iderztification and characterization of a novel nuclear-factor of activated T-cells-I isoform expressed in mouse brain", J BIOL CHEM, vol. 276, no. 17, 2001, pages 14350 - 8
PRITCHARD, J.; PRZEWORSKI, M., AM. J. HUM. GENET., vol. 69, 2001, pages 1 - 14
PULVER, A.E.; LASSETER, V.K.; KASCH, L.; WOLYNIEC, P.; NESTADT, G.; BLOUIN, J.L.; KIMBERLAND, M.; BABB, R.; VOURLIS, S.; CHEN, H.: "Schizophrenia: a genome scan targets chromosomes 3p and 8p as potential sites of susceptibility genes", AM JMED GENET, vol. 60, 1995, pages 252 - 60
QUEEN ET AL., CELL, vol. 33, 1983, pages 741
ROTHERMUNDT, M.; V. AROLT; T.A. BAYER: "Review of immunological and immullopathological findings in schizophrenia", BRAIN BEHAV IMMUN, vol. 15, no. 4, 2001, pages 319 - 39
RUBINSTEIN, G.; SCHIZOPHRENIA: "rheumatoid arthritis and natural resistance genes", SCHIZOPHR RES, vol. 25, no. 3, 1997, pages 177 - 81
RUSNAK, F.; MERTZ, P., PHYSIOLOGICAL REVIEWS, vol. 80, no. 4, 2000, pages 1483 - 1522
SAIKI, R. ET AL., NATURE (LONDON), vol. 324, 1986, pages 163 - 166
SAKIC, B.; H. SZECHTMAN; J.A. DENBURG: "Neurobehavioral alterations in autoimmune mice", NEUROSCI BIOBEHAV REV, vol. 21, no. 3, 1997, pages 327 - 40
SAMBASIVARAO, D. ET AL.: "A novel immunosuppressive factor in bovine colostrum blocks activation of the interleukin 2 gene enhancer at the NFAT site", BIOCHEM CELL BIOL, vol. 74, no. 4, 1996, pages 585 - 93
SAMBASIVARAO, D. ET AL.: "A novel immunosuppressive factor in bovine colostrum blocks activation of the interleukin 2 gene enhancer at the NFAT site.", BIOCHEM CELL BIOL, vol. 74, no. 4, 1996, pages 585 - 93
SANGER, F. ET AL., PROC. NATL. ACAD. SCI., vol. 74, 1977, pages 5463 - 5467
SCHWAB, S. G.; ECKSTEIN, G. N.; HALLMAYER, J.; LERER, B.; ALBUS, M.; BORRMANN, M.; LICHTERMANN, D.; ERTL, M. A.; MAIER, W.; WILDEN, MOL. PSYCHIATRY., vol. 2, no. 2, March 1997 (1997-03-01), pages 156 - 60
SCHWARTZ, M.; H. SILVER: "Lymphocytes, autoantibodies and psychosis-coincidence vet sus etiological factor; an update", ISR J PSYCHIATRY RELAT SCI, vol. 37, no. 1, 2000, pages 32 - 6
SEEMAN, P, SYNAPSE, vol. 1, 1987, pages 133 - 52
SERAFINI, T. ET AL., IMMURTITY, vol. 3, 1995, pages 239 - 250
SEREBRIISKII, I.G. ET AL., METHODS MOL BIOL, vol. 175, 2001, pages 415 - 54
SHAW, J.P. ET AL., SCIENCE, vol. 241, 1988, pages 202 - 205
SHEFFIELD, V. C. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 86, pages 232 - 236
SHIBASAKI, F.; HALLIN, U.; UCHINO, H., J BIOCHEM (TOKYO), vol. 131, 2002, pages 1 - 15
SNYDER, G.L. ET AL.: "Phosphorylation of DARPP-32 and protein phosphatase inhibitor-1 in rat choroid plexus: regulation by factors other than dopamine", J NEUROSCI, vol. 12, no. 8, 1992, pages 3071 - 83
SNYDER, G.L. ET AL.: "Phosphotylation ofDARPP-32 and protein phosphatase inhibitor-l in rat choroid plexus: regulation by factors other than dopamine", J NEUROSCI, vol. 12, no. 8, 1992, pages 3071 - 83
SNYDER, S.H.; LAI, M.M.; BURNETT, P.E.: "Immumophilins in the nervous system", NEURON, vol. 21, 1998, pages 283 - 94
SNYDER, S.H.; SABATINI, D.M.; LAI, M.M.; STEINER, J.P.; HAMILTON, G.S.; SUZDAK, P.D.: "Neural actions of immunophilin ligands", TRENDS PHARMACOL SCI, vol. 19, 1998, pages 21 - 6
SOBIN, C.; BLUNDELL, M. L.; CONRY, A.; WEILLER, F.; GAVIGAN, C.; HAIMAN, C.; KARAYIORGOU, M., PSYCHIATRY RES., vol. 101, 2001, pages 101 - 113
STEFANNSON, H. ET AL., AM. J. HUM. GENET., vol. 71, 2002, pages 877 - 892
STOBER, G.; SAAR, K.; RUSCHENDORF, F.; MEYER, J.; NURNBERG, G.; JATZKE, S.; FRANZEK, E.; REIS, A.; LESCH, K.P.; WIENKER, T.F.: "Splitting schizophrenia: periodic catatonia-susceptibility locus on chromosome 15q15", AM JHUM GENET, vol. 67, 2000, pages 1201 - 7
STOBER, G.; SAAR, K.; RUSCHENDORF, F.; MEYER, J.; NURNBERG, G.; JATZKE, S.; FRANZEK, E.; REIS, A.; LESCH, K.P.; WIENKER, T.F.: "Splitting schizophrenia: periodic catatonia-susceptibility locus on chromosome 15ql5", AM JHUM GENET, vol. 67, 2000, pages 1201 - 7
STRAUB, R. E.; MACLEAN, C. J.; MA, Y.; WEBB, B. T.; MYAKISHEV, M. V.; HARRIS-KERR, C.; WORMLEY, B.; SADEK, H.; KADAMBI, B.; O'NEIL, MOL PSYCHIATRY., vol. 7, no. 6, 2002, pages 542 - 59
STRAUB, R.E. ET AL., ANA. J. HUM. GENET., vol. 71, 2002, pages 337 - 348
SUI, G. ET AL., PROC. NATL. ACAD. SCI., vol. 99, no. 8, 2002, pages 5515 - 5520
SUN ET AL., PHARMACOL. REV., vol. 52, 2000, pages 325
SUN, L. ET AL.: "Cabin 1, a negative regulator for calcineurin signaling in T lymphocytes", IMMUNITY, vol. 8, no. 6, 1998, pages 703 - 11
TAIRA, K., NAT. BIOTECH., vol. 20, 2002, pages 497 - 500
TAKESHIMA, H.; IKEMOTO, T.; NISHI, M.; NISHIYAMA, N.; SHIMUTA, M.; SUGITANI, Y.; KUNO, J.; SAITO, I.; SAITO, H.; ENDO, M.: "Generation and characterization of mutant mice lacking ryanodine receptor type 3", JBIOL CHEM, vol. 271, 1996, pages 19649 - 52
TAN ET AL.: "Stereoselective Synthesis of Over Two Million Compounds Having Structural Features Both Reminiscent of Natural Products and Compatible with Miniaturized Cell-Based Assays", AM. CHEM SOC., vol. 120, 1998, pages 8565 - 8566
TERRYN; ROUZE, TRENDS PLANT SCI., vol. 5, 2000, pages 1360
THAKER, G. K.; CARPENTER, W. T., JR, NATMED, vol. 7, 2001, pages 667 - 71
THAKER, G. K.; CARPENTER, W. T., JR., NAT MED, vol. 7, 2041, pages 667 - 71
THAKER, G.K.; CARPENTER, W.T., JR.: "Advances in schizophrenia", NAT MED, vol. 7, 2001, pages 667 - 71
TIMMERMAN, L. ET AL., NATURE, vol. 383, 1996, pages 837 - 40
TORII, N. ET AL.: "An inhibitor for calcineurin, FK506, blocks induction of long-term depression in rat visual cortex", NEUROSCI LETT, vol. 185, no. 1, 1995, pages 1 - 4
TUSCHL, T., NAT. BIOTECHNOL., vol. 20, May 2002 (2002-05-01), pages 446 - 448
UNDERHILL, P.A. ET AL., GENOME RESEARCH, vol. 7, no. 10, 1997, pages 996 - 1005
USISKIN, S. I. ET AL., J. AM. ACAD. CHILD ADOLESC. PSYCHIANY, vol. 38, 1999, pages 1536 - 1543
USMAN ET AL., CURR. OPIN. STRUCT. BIOL., vol. 1, 1996, pages 527
USMAN, NUCL. ACIDS MOL. BIOL., vol. 10, 1996, pages 243
VARGA ET AL., IMMUN. LETT., vol. 69, 1999, pages 217
VAUGHAN ET AL., NATUT-E BIOTECHNOLOGY, vol. 16, 1998, pages 535 - 539
VIDAL, M.; ENDOH, H., TRENDS BIOTECHNOL, vol. 17, no. 9, September 1999 (1999-09-01), pages 374 - 81
WAGNER, NAT. MEDICINE, vol. 1, 1995, pages 1116
WALL, J., CURR. OP. NEUROBIOL, vol. 11, 2001, pages 647 - 651
WATANABE, T. ET AL., PROC NATL ACAD SCI USA, vol. 98, no. 6, 13 March 2001 (2001-03-13), pages 3080 - 5
WINOTO ET AL., EMBO J., vol. 8, 1989, pages 729
WOOLF, NUCLEIC ACIDS RES., vol. 18, 1990, pages 1763
WRIGHT, P.; DONALDSON, P.T.; UNDERHILL, J.A.; CHOUDHURI, K.; DOHERTY, D.G.; MURRAY, R.M.: "Genetic association of the HLA DRB gene locus on chromosome 6p21.3 with schizophrenia", AM J PSYCHIATRY, vol. 153, 1996, pages 1530 - 3
WRIGHT, P.; DONALDSON, P.T.; UNDERHILL, J.A.; CHOUDHURI, K.; DOHERTY, D.G.; MURRAY, R.M.: "Genetic association of the HLA DRB1 gene locus on chromosome 6p21.3 with schizophrenia", AM JPSYCHIATRY, vol. 153, 1996, pages 1530 - 3
WU; WALLACE, GENOMICS, vol. 4, 1989, pages 560
XENG, H. ET AL., CELL, vol. 107, 1991, pages 617 - 629
XU ET AL., GENE THERAPY, vol. 7, 2000, pages 438
YAKEL, J., TRENDS IN PHARMACOLOGICAL SCIENCE, vol. 18, 1997, pages 124 - 134
YU, J. ET AL., PROC. NATL. ACAD. SCI., vol. 99, no. 9, 2002, pages 6047 - 6052
ZENG, H. ET AL., CELL, vol. 107, 1991, pages 617 - 629
ZENG, H. ET AL., CELL, vol. 107, 2001, pages 617 - 29
ZENG, H. ET AL.: "Forebrain-specific calcineurin knockout selectively impairs bidir-ectional synaptic plasticity and working/episodic-like memory", CELL, vol. 107, no. 5, 2001, pages 617 - 29
ZENG, H.; CHATTARJI, S.; BARBAROSIE, M.; RONDI-REIG, L.; PLLILPOT, B.D.; MIYAKAWA, T.; BEAR, M.F.; TONEGAWA, S.: "Forebrain-specific calcineurin knockout selectively impairs bidirectional synaptic plasticity and working/episodic-like memory", CELL, vol. 107, 2001, pages 617 - 29
ZENG, Y. ET AL., MOLECULAR CELL, vol. 9, 2002, pages 1 - 20
ZHUO, M. ET AL.: "A selective role of calcineurin aalpha in synaptic depotentiation in hippocampus", PROC NATL ACAD SCI U S A, vol. 96, no. 8, 1999, pages 4650 - 5

Also Published As

Publication number Publication date
US20110172158A1 (en) 2011-07-14
EP1578354A4 (fr) 2008-04-09
US20040014095A1 (en) 2004-01-22
EP1578354A2 (fr) 2005-09-28
AU2003233451A1 (en) 2003-10-13
WO2003082210A3 (fr) 2007-01-04
US20110288027A1 (en) 2011-11-24
CA2481238A1 (fr) 2003-10-09
US7935500B2 (en) 2011-05-03
WO2003082210A2 (fr) 2003-10-09
JP2009189373A (ja) 2009-08-27
JP2006507795A (ja) 2006-03-09
EP2270197A3 (fr) 2011-02-16
AU2003233451A8 (en) 2003-10-13
JP4544865B2 (ja) 2010-09-15

Similar Documents

Publication Publication Date Title
US7935500B2 (en) Identifying calcineurin activators for treatment of schizophrenia
US9486541B2 (en) Detecting and treating dementia
US20080146540A1 (en) Methods of diagnosis and treatment for asthma, allergic rhinitis and other respiratory diseases based on haplotype association
WO2010005750A2 (fr) Marqueurs pronostics et cibles thérapeutiques potentiels pour troubles neurologiques
Depienne et al. Association of rare genetic variants in opioid receptors with Tourette syndrome
US20050158733A1 (en) EGR genes as targets for the diagnosis and treatment of schizophrenia
EP1656458B1 (fr) Gene humain de susceptibilite a l&#39;autisme et ses utilisations
EP2687223B1 (fr) Detection et traitement de la démence
US20080261231A1 (en) Diabetes gene
JP2008537486A (ja) 膜貫通タンパク質をコード化するヒトの自閉症感受性遺伝子およびその使用
Van Belzen et al. Genetic analysis of psychiatric disorders in humans
US20050196784A1 (en) Human Type II diabetes gene - Kv channel-interacting protein (KChIP1) located on chromosome 5
US8067158B2 (en) Methods and compositions for the diagnosis and treatment of schizophrenia
CA2858526A1 (fr) Cibles moleculaires pour la sla et les troubles apparentes
US20030224423A1 (en) Method of testing for allergic diseases
EP1514119A2 (fr) Polymorphisme diagnostique de la 11 -hydroxyst ro de d shydrog nase utile pour identifier le risque de d veloppement de la maladie d&#39;alzheimer
WO2007101991A1 (fr) Cible pour l&#39;amélioration d&#39;une fonction cognitive

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 1578354

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KARAYIORGOU, MARIA

Inventor name: GERBER, DAVID J

Inventor name: TONEGAWA, SUSUMU

Inventor name: MIYAKAWA, TSUYOSHI

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

17P Request for examination filed

Effective date: 20110810

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120522